10-Q 1 tv537248-10q.htm FORM 10-Q
TABLE OF CONTENTS
​
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
​
FORM 10-Q
​
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
​
For the quarterly period ended December 31, 2019
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
​
For the transition period from _____ to _____
Commission File Number: 001-36410
​
Phibro Animal Health Corporation
(Exact name of registrant as specified in its charter)

​ | Delaware | ​ | ​ | 13-1840497 | ​
​ | (State or other jurisdiction of incorporation or organization) | ​ | ​ | (I.R.S. Employer Identification No.) | ​
​ | Glenpointe Centre East, 3rd Floor 300 Frank W. Burr Boulevard, Suite 21 Teaneck, New Jersey (Address of Principal Executive Offices) | ​ | ​ | 07666-6712 (Zip Code) | ​

(201) 329-7300
(Registrant’s telephone number, including area code)
​
Securities registered pursuant to Section 12(b) of the Act:

​ | Title of each class | ​ | ​ | Trading Symbol(s) | ​ | ​ | Name of each exchange on which registered | ​
​ | Class A Common Stock, $0.0001 par value per share | ​ | ​ | PAHC | ​ | ​ | Nasdaq Stock Market | ​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)  Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of  “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​ | Large accelerated filer | ​ | ​ | ☐ | ​ | ​ | Accelerated filer | ​ | ​ | ☒ | ​
​ | Non-accelerated filer | ​ | ​ | ☐ | ​ | ​ | Smaller reporting company | ​ | ​ | ☐ | ​
​ | Emerging growth company | ​ | ​ | ☐ | ​ | ​ | ​ | ​ | ​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act). Yes ☐ No ☒
As of January 28, 2020, there were 20,287,574 shares of the registrant’s Class A common stock, par value $0.0001 per share, and 20,166,034 shares of the registrant’s Class B common stock, par value $0.0001 per share, outstanding.
​
​

TABLE OF CONTENTS​
PHIBRO ANIMAL HEALTH CORPORATION
TABLE OF CONTENTS

​ | ​ | ​ | Page | ​
PART I—FINANCIAL INFORMATION | ​ | ​ | ​ | ​ | ​ | ​ | ​
Item 1. Financial Statements (unaudited) ​ | ​ | ​ | ​ | ​ | 3 | ​ | ​
Consolidated Statements of Operations | ​ | ​ | ​ | ​ | 3 | ​ | ​
Consolidated Statements of Comprehensive Income | ​ | ​ | ​ | ​ | 4 | ​ | ​
Consolidated Balance Sheets | ​ | ​ | ​ | ​ | 5 | ​ | ​
Consolidated Statements of Cash Flows | ​ | ​ | ​ | ​ | 6 | ​ | ​
Consolidated Statements of Changes in Stockholders’ Equity | ​ | ​ | ​ | ​ | 7 | ​ | ​
Notes to Consolidated Financial Statements | ​ | ​ | ​ | ​ | 8 | ​ | ​
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations ​ | ​ | ​ | ​ | ​ | 22 | ​ | ​
Item 3. Quantitative and Qualitative Disclosures About Market Risk ​ | ​ | ​ | ​ | ​ | 34 | ​ | ​
Item 4. Controls and Procedures ​ | ​ | ​ | ​ | ​ | 34 | ​ | ​
PART II—OTHER INFORMATION | ​ | ​ | ​ | ​ | ​ | ​ | ​
Item 1. Legal Proceedings ​ | ​ | ​ | ​ | ​ | 36 | ​ | ​
Item 1A. Risk Factors ​ | ​ | ​ | ​ | ​ | 36 | ​ | ​
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds ​ | ​ | ​ | ​ | ​ | 36 | ​ | ​
Item 3. Defaults Upon Senior Securities ​ | ​ | ​ | ​ | ​ | 36 | ​ | ​
Item 4. Mine Safety Disclosures ​ | ​ | ​ | ​ | ​ | 36 | ​ | ​
Item 5. Other Information ​ | ​ | ​ | ​ | ​ | 36 | ​ | ​
SIGNATURES | ​ | ​ | ​ | ​ | 37 | ​ | ​

2

TABLE OF CONTENTS​​​
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements
PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS

​ | ​ | ​ | Three Months | ​ | ​ | Six Months | ​
For the Periods Ended December 31 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​
​ | ​ | ​ | (unaudited) (in thousands, except per share amounts) | ​
Net sales | ​ | ​ | ​ | $ | 214,012 | ​ | ​ | ​ | ​ | $ | 218,223 | ​ | ​ | ​ | ​ | $ | 403,732 | ​ | ​ | ​ | ​ | $ | 418,376 | ​ | ​
Cost of goods sold | ​ | ​ | ​ | ​ | 144,908 | ​ | ​ | ​ | ​ | ​ | 149,579 | ​ | ​ | ​ | ​ | ​ | 276,965 | ​ | ​ | ​ | ​ | ​ | 283,927 | ​ | ​
Gross profit | ​ | ​ | ​ | ​ | 69,104 | ​ | ​ | ​ | ​ | ​ | 68,644 | ​ | ​ | ​ | ​ | ​ | 126,767 | ​ | ​ | ​ | ​ | ​ | 134,449 | ​ | ​
Selling, general and administrative expenses | ​ | ​ | ​ | ​ | 49,495 | ​ | ​ | ​ | ​ | ​ | 42,938 | ​ | ​ | ​ | ​ | ​ | 97,011 | ​ | ​ | ​ | ​ | ​ | 85,890 | ​ | ​
Operating income | ​ | ​ | ​ | ​ | 19,609 | ​ | ​ | ​ | ​ | ​ | 25,706 | ​ | ​ | ​ | ​ | ​ | 29,756 | ​ | ​ | ​ | ​ | ​ | 48,559 | ​ | ​
Interest expense, net | ​ | ​ | ​ | ​ | 3,432 | ​ | ​ | ​ | ​ | ​ | 3,015 | ​ | ​ | ​ | ​ | ​ | 6,786 | ​ | ​ | ​ | ​ | ​ | 5,798 | ​ | ​
Foreign currency (gains) losses, net | ​ | ​ | ​ | ​ | (718) | ​ | ​ | ​ | ​ | ​ | 2,617 | ​ | ​ | ​ | ​ | ​ | 2,503 | ​ | ​ | ​ | ​ | ​ | (18) | ​ | ​
Income before income taxes | ​ | ​ | ​ | ​ | 16,895 | ​ | ​ | ​ | ​ | ​ | 20,074 | ​ | ​ | ​ | ​ | ​ | 20,467 | ​ | ​ | ​ | ​ | ​ | 42,779 | ​ | ​
Provision for income taxes | ​ | ​ | ​ | ​ | 5,001 | ​ | ​ | ​ | ​ | ​ | 5,326 | ​ | ​ | ​ | ​ | ​ | 6,058 | ​ | ​ | ​ | ​ | ​ | 11,717 | ​ | ​
Net income | ​ | ​ | ​ | $ | 11,894 | ​ | ​ | ​ | ​ | $ | 14,748 | ​ | ​ | ​ | ​ | $ | 14,409 | ​ | ​ | ​ | ​ | $ | 31,062 | ​ | ​
Net income per share | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
basic | ​ | ​ | ​ | $ | 0.29 | ​ | ​ | ​ | ​ | $ | 0.37 | ​ | ​ | ​ | ​ | $ | 0.36 | ​ | ​ | ​ | ​ | $ | 0.77 | ​ | ​
diluted | ​ | ​ | ​ | $ | 0.29 | ​ | ​ | ​ | ​ | $ | 0.36 | ​ | ​ | ​ | ​ | $ | 0.36 | ​ | ​ | ​ | ​ | $ | 0.77 | ​ | ​
Weighted average common shares outstanding | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
basic | ​ | ​ | ​ | ​ | 40,454 | ​ | ​ | ​ | ​ | ​ | 40,383 | ​ | ​ | ​ | ​ | ​ | 40,454 | ​ | ​ | ​ | ​ | ​ | 40,376 | ​ | ​
diluted | ​ | ​ | ​ | ​ | 40,504 | ​ | ​ | ​ | ​ | ​ | 40,523 | ​ | ​ | ​ | ​ | ​ | 40,504 | ​ | ​ | ​ | ​ | ​ | 40,523 | ​ | ​

The accompanying notes are an integral part of these consolidated financial statements
3

TABLE OF CONTENTS​
PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

​ | ​ | ​ | Three Months | ​ | ​ | Six Months | ​
For the Periods Ended December 31 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​
​ | ​ | ​ | (unaudited) (in thousands) | ​
Net income | ​ | ​ | ​ | $ | 11,894 | ​ | ​ | ​ | ​ | $ | 14,748 | ​ | ​ | ​ | ​ | $ | 14,409 | ​ | ​ | ​ | ​ | $ | 31,062 | ​ | ​
Change in fair value of derivative instruments | ​ | ​ | ​ | ​ | 1,080 | ​ | ​ | ​ | ​ | ​ | (2,243) | ​ | ​ | ​ | ​ | ​ | (4) | ​ | ​ | ​ | ​ | ​ | (1,702) | ​ | ​
Foreign currency translation adjustment | ​ | ​ | ​ | ​ | 2,203 | ​ | ​ | ​ | ​ | ​ | 4,163 | ​ | ​ | ​ | ​ | ​ | (4,620) | ​ | ​ | ​ | ​ | ​ | (3,519) | ​ | ​
Unrecognized net pension gains (losses) | ​ | ​ | ​ | ​ | 138 | ​ | ​ | ​ | ​ | ​ | 124 | ​ | ​ | ​ | ​ | ​ | 258 | ​ | ​ | ​ | ​ | ​ | 232 | ​ | ​
(Provision) benefit for income taxes | ​ | ​ | ​ | ​ | (303) | ​ | ​ | ​ | ​ | ​ | 527 | ​ | ​ | ​ | ​ | ​ | (63) | ​ | ​ | ​ | ​ | ​ | 365 | ​ | ​
Other comprehensive income (loss) | ​ | ​ | ​ | ​ | 3,118 | ​ | ​ | ​ | ​ | ​ | 2,571 | ​ | ​ | ​ | ​ | ​ | (4,429) | ​ | ​ | ​ | ​ | ​ | (4,624) | ​ | ​
Comprehensive income (loss) | ​ | ​ | ​ | $ | 15,012 | ​ | ​ | ​ | ​ | $ | 17,319 | ​ | ​ | ​ | ​ | $ | 9,980 | ​ | ​ | ​ | ​ | $ | 26,438 | ​ | ​

The accompanying notes are an integral part of these consolidated financial statements
4

TABLE OF CONTENTS​
PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

As of | ​ | ​ | December 31, 2019 | ​ | ​ | June 30, 2019 | ​
​ | ​ | ​ | (unaudited) (in thousands, except share and per share amounts) | ​
ASSETS | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash and cash equivalents | ​ | ​ | ​ | $ | 26,180 | ​ | ​ | ​ | ​ | $ | 57,573 | ​ | ​
Short-term investments | ​ | ​ | ​ | ​ | 49,000 | ​ | ​ | ​ | ​ | ​ | 24,000 | ​ | ​
Accounts receivable, net | ​ | ​ | ​ | ​ | 147,441 | ​ | ​ | ​ | ​ | ​ | 159,022 | ​ | ​
Inventories, net | ​ | ​ | ​ | ​ | 193,509 | ​ | ​ | ​ | ​ | ​ | 198,322 | ​ | ​
Other current assets | ​ | ​ | ​ | ​ | 29,357 | ​ | ​ | ​ | ​ | ​ | 27,245 | ​ | ​
Total current assets | ​ | ​ | ​ | ​ | 445,487 | ​ | ​ | ​ | ​ | ​ | 466,162 | ​ | ​
Property, plant and equipment, net | ​ | ​ | ​ | ​ | 144,733 | ​ | ​ | ​ | ​ | ​ | 140,235 | ​ | ​
Intangibles, net | ​ | ​ | ​ | ​ | 75,541 | ​ | ​ | ​ | ​ | ​ | 47,478 | ​ | ​
Goodwill | ​ | ​ | ​ | ​ | 52,679 | ​ | ​ | ​ | ​ | ​ | 27,348 | ​ | ​
Other assets | ​ | ​ | ​ | ​ | 69,878 | ​ | ​ | ​ | ​ | ​ | 45,448 | ​ | ​
Total assets | ​ | ​ | ​ | $ | 788,318 | ​ | ​ | ​ | ​ | $ | 726,671 | ​ | ​
LIABILITIES AND STOCKHOLDERS’ EQUITY | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Current portion of long-term debt | ​ | ​ | ​ | $ | 15,625 | ​ | ​ | ​ | ​ | $ | 12,540 | ​ | ​
Accounts payable | ​ | ​ | ​ | ​ | 58,263 | ​ | ​ | ​ | ​ | ​ | 73,189 | ​ | ​
Accrued expenses and other current liabilities | ​ | ​ | ​ | ​ | 73,171 | ​ | ​ | ​ | ​ | ​ | 68,498 | ​ | ​
Total current liabilities | ​ | ​ | ​ | ​ | 147,059 | ​ | ​ | ​ | ​ | ​ | 154,227 | ​ | ​
Revolving credit facility | ​ | ​ | ​ | ​ | 149,000 | ​ | ​ | ​ | ​ | ​ | 96,000 | ​ | ​
Long-term debt | ​ | ​ | ​ | ​ | 208,446 | ​ | ​ | ​ | ​ | ​ | 217,635 | ​ | ​
Other liabilities | ​ | ​ | ​ | ​ | 66,398 | ​ | ​ | ​ | ​ | ​ | 42,794 | ​ | ​
Total liabilities | ​ | ​ | ​ | ​ | 570,903 | ​ | ​ | ​ | ​ | ​ | 510,656 | ​ | ​
Commitments and contingencies (Note 9) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Common stock, par value $0.0001 per share; 300,000,000 Class A shares authorized, 20,287,574 shares issued and outstanding at December 31, 2019 and June 30, 2019; 30,000,000 Class B shares authorized, 20,166,034 shares issued and outstanding at December 31, 2019 and June 30, 2019 | ​ | ​ | ​ | ​ | 4 | ​ | ​ | ​ | ​ | ​ | 4 | ​ | ​
Preferred stock, par value $0.0001 per share; 16,000,000 shares authorized, no shares issued and outstanding | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​
Paid-in capital | ​ | ​ | ​ | ​ | 134,395 | ​ | ​ | ​ | ​ | ​ | 133,266 | ​ | ​
Retained earnings | ​ | ​ | ​ | ​ | 173,626 | ​ | ​ | ​ | ​ | ​ | 168,926 | ​ | ​
Accumulated other comprehensive income (loss) | ​ | ​ | ​ | ​ | (90,610) | ​ | ​ | ​ | ​ | ​ | (86,181) | ​ | ​
Total stockholders’ equity | ​ | ​ | ​ | ​ | 217,415 | ​ | ​ | ​ | ​ | ​ | 216,015 | ​ | ​
Total liabilities and stockholders’ equity | ​ | ​ | ​ | $ | 788,318 | ​ | ​ | ​ | ​ | $ | 726,671 | ​ | ​
​

The accompanying notes are an integral part of these consolidated financial statements
5

TABLE OF CONTENTS​
PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

​ | ​ | ​ | Six Months | ​
For the Periods Ended December 31 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​
​ | ​ | ​ | (unaudited) (in thousands) | ​
OPERATING ACTIVITIES | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income | ​ | ​ | ​ | $ | 14,409 | ​ | ​ | ​ | ​ | $ | 31,062 | ​ | ​
Adjustments to reconcile net income to net cash provided (used) by operating activities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Depreciation and amortization | ​ | ​ | ​ | ​ | 15,929 | ​ | ​ | ​ | ​ | ​ | 13,532 | ​ | ​
Amortization of debt issuance costs and debt discount | ​ | ​ | ​ | ​ | 442 | ​ | ​ | ​ | ​ | ​ | 441 | ​ | ​
Stock-based compensation | ​ | ​ | ​ | ​ | 1,129 | ​ | ​ | ​ | ​ | ​ | 1,129 | ​ | ​
Acquisition-related costs of goods sold | ​ | ​ | ​ | ​ | 280 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​
Acquisition-related accrued interest | ​ | ​ | ​ | ​ | 132 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​
Deferred income taxes | ​ | ​ | ​ | ​ | (565) | ​ | ​ | ​ | ​ | ​ | 135 | ​ | ​
Foreign currency (gains) losses, net | ​ | ​ | ​ | ​ | (132) | ​ | ​ | ​ | ​ | ​ | 12 | ​ | ​
Other | ​ | ​ | ​ | ​ | 374 | ​ | ​ | ​ | ​ | ​ | (1,071) | ​ | ​
Changes in operating assets and liabilities, net of business acquisitions: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Accounts receivable, net | ​ | ​ | ​ | ​ | 12,906 | ​ | ​ | ​ | ​ | ​ | (8,906) | ​ | ​
Inventories, net | ​ | ​ | ​ | ​ | 3,412 | ​ | ​ | ​ | ​ | ​ | (16,278) | ​ | ​
Other current assets | ​ | ​ | ​ | ​ | (2,300) | ​ | ​ | ​ | ​ | ​ | (3,616) | ​ | ​
Other assets | ​ | ​ | ​ | ​ | (1,395) | ​ | ​ | ​ | ​ | ​ | 866 | ​ | ​
Accounts payable | ​ | ​ | ​ | ​ | (14,108) | ​ | ​ | ​ | ​ | ​ | 5,169 | ​ | ​
Accrued expenses and other liabilities | ​ | ​ | ​ | ​ | (1,992) | ​ | ​ | ​ | ​ | ​ | (5,839) | ​ | ​
Net cash (used) provided by operating activities | ​ | ​ | ​ | ​ | 28,521 | ​ | ​ | ​ | ​ | ​ | 16,636 | ​ | ​
INVESTING ACTIVITIES | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Purchases of short-term investments | ​ | ​ | ​ | ​ | (25,000) | ​ | ​ | ​ | ​ | ​ | (10,000) | ​ | ​
Maturities of short-term investments | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 11,000 | ​ | ​
Capital expenditures | ​ | ​ | ​ | ​ | (16,115) | ​ | ​ | ​ | ​ | ​ | (12,117) | ​ | ​
Business acquisitions | ​ | ​ | ​ | ​ | (54,549) | ​ | ​ | ​ | ​ | ​ | (9,838) | ​ | ​
Other, net | ​ | ​ | ​ | ​ | (1,045) | ​ | ​ | ​ | ​ | ​ | 27 | ​ | ​
Net cash (used) by investing activities | ​ | ​ | ​ | ​ | (96,709) | ​ | ​ | ​ | ​ | ​ | (20,928) | ​ | ​
FINANCING ACTIVITIES | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Revolving credit facility borrowings | ​ | ​ | ​ | ​ | 155,000 | ​ | ​ | ​ | ​ | ​ | 103,000 | ​ | ​
Revolving credit facility repayments | ​ | ​ | ​ | ​ | (102,000) | ​ | ​ | ​ | ​ | ​ | (85,000) | ​ | ​
Payments of long-term debt and other | ​ | ​ | ​ | ​ | (6,361) | ​ | ​ | ​ | ​ | ​ | (6,359) | ​ | ​
Issuance of acquisition note payable | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 3,775 | ​ | ​
Proceeds from common shares issued | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 341 | ​ | ​
Dividends paid | ​ | ​ | ​ | ​ | (9,709) | ​ | ​ | ​ | ​ | ​ | (8,883) | ​ | ​
Net cash used by financing activities | ​ | ​ | ​ | ​ | 36,930 | ​ | ​ | ​ | ​ | ​ | 6,874 | ​ | ​
Effect of exchange rate changes on cash | ​ | ​ | ​ | ​ | (135) | ​ | ​ | ​ | ​ | ​ | (414) | ​ | ​
Net increase (decrease) in cash and cash equivalents | ​ | ​ | ​ | ​ | (31,393) | ​ | ​ | ​ | ​ | ​ | 2,168 | ​ | ​
Cash and cash equivalents at beginning of period | ​ | ​ | ​ | ​ | 57,573 | ​ | ​ | ​ | ​ | ​ | 29,168 | ​ | ​
Cash and cash equivalents at end of period | ​ | ​ | ​ | $ | 26,180 | ​ | ​ | ​ | ​ | $ | 31,336 | ​ | ​

The accompanying notes are an integral part of these consolidated financial statements
6

TABLE OF CONTENTS​
PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

​ | ​ | ​ | Shares of Common Stock | ​ | ​ | Common Stock | ​ | ​ | Preferred Stock | ​ | ​ | Paid-in Capital | ​ | ​ | Retained Earnings | ​ | ​ | Accumulated Other Comprehensive Income (Loss) | ​ | ​ | Total | ​
​ | ​ | ​ | (in thousands, except share amounts) | ​
As of June 30, 2019 | ​ | ​ | ​ | ​ | 40,453,608 | ​ | ​ | ​ | ​ | $ | 4 | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 133,266 | ​ | ​ | ​ | ​ | $ | 168,926 | ​ | ​ | ​ | ​ | $ | (86,181) | ​ | ​ | ​ | ​ | $ | 216,015 | ​ | ​
Comprehensive income (loss) | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 2,515 | ​ | ​ | ​ | ​ | ​ | (7,547) | ​ | ​ | ​ | ​ | ​ | (5,032) | ​ | ​
Dividends declared ($0.12/share) | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (4,854) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (4,854) | ​ | ​
Stock-based compensation expense | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 565 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 565 | ​ | ​
As of September 30, 2019 | ​ | ​ | ​ | ​ | 40,453,608 | ​ | ​ | ​ | ​ | $ | 4 | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 133,831 | ​ | ​ | ​ | ​ | $ | 166,587 | ​ | ​ | ​ | ​ | $ | (93,728) | ​ | ​ | ​ | ​ | $ | 206,694 | ​ | ​
Comprehensive income (loss) | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 11,894 | ​ | ​ | ​ | ​ | ​ | 3,118 | ​ | ​ | ​ | ​ | ​ | 15,012 | ​ | ​
Dividends declared ($0.12/share) | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (4,855) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (4,855) | ​ | ​
Stock-based compensation expense | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 564 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 564 | ​ | ​
As of December 31, 2019 | ​ | ​ | ​ | ​ | 40,453,608 | ​ | ​ | ​ | ​ | $ | 4 | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 134,395 | ​ | ​ | ​ | ​ | $ | 173,626 | ​ | ​ | ​ | ​ | $ | (90,610) | ​ | ​ | ​ | ​ | $ | 217,415 | ​ | ​
​

​ | ​ | ​ | Shares of Common Stock | ​ | ​ | Common Stock | ​ | ​ | Preferred Stock | ​ | ​ | Paid-in Capital | ​ | ​ | Retained Earnings | ​ | ​ | Accumulated Other Comprehensive Income (Loss) | ​ | ​ | Total | ​
​ | ​ | ​ | (in thousands, except share amounts) | ​
As of June 30, 2018 | ​ | ​ | ​ | ​ | 40,357,708 | ​ | ​ | ​ | ​ | $ | 4 | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 129,873 | ​ | ​ | ​ | ​ | $ | 131,560 | ​ | ​ | ​ | ​ | $ | (76,483) | ​ | ​ | ​ | ​ | $ | 184,954 | ​ | ​
Adoption of new revenue standard | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 1,245 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 1,245 | ​ | ​
Comprehensive income (loss) | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 16,314 | ​ | ​ | ​ | ​ | ​ | (7,195) | ​ | ​ | ​ | ​ | ​ | 9,119 | ​ | ​
Exercise of stock options | ​ | ​ | ​ | ​ | 17,860 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 211 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 211 | ​ | ​
Dividends declared ($0.10/share) | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (4,037) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (4,037) | ​ | ​
Stock-based compensation expense | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 565 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 565 | ​ | ​
As of September 30, 2018 | ​ | ​ | ​ | ​ | 40,375,568 | ​ | ​ | ​ | ​ | $ | 4 | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 130,649 | ​ | ​ | ​ | ​ | $ | 145,082 | ​ | ​ | ​ | ​ | $ | (83,678) | ​ | ​ | ​ | ​ | $ | 192,057 | ​ | ​
Comprehensive income (loss) | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 14,748 | ​ | ​ | ​ | ​ | ​ | 2,571 | ​ | ​ | ​ | ​ | ​ | 17,319 | ​ | ​
Exercise of stock options | ​ | ​ | ​ | ​ | 11,000 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 130 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 130 | ​ | ​
Dividends declared ($0.12/share) | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (4,846) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (4,846) | ​ | ​
Stock-based compensation expense | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 564 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 564 | ​ | ​
As of December 31, 2018 | ​ | ​ | ​ | ​ | 40,386,568 | ​ | ​ | ​ | ​ | $ | 4 | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 131,343 | ​ | ​ | ​ | ​ | $ | 154,984 | ​ | ​ | ​ | ​ | $ | (81,107) | ​ | ​ | ​ | ​ | $ | 205,224 | ​ | ​

The accompanying notes are an integral part of these consolidated financial statements
7

TABLE OF CONTENTS​
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share amounts)
(unaudited)
1.
Description of Business
​
Phibro Animal Health Corporation (“Phibro” or “PAHC”) and its subsidiaries (together, the “Company”) is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for food animals including poultry, swine, dairy and beef cattle, and aquaculture. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Unless otherwise indicated or the context requires otherwise, references in this report to “we,” “our,” “us,” and similar expressions refer to Phibro and its subsidiaries.
The unaudited consolidated financial information for the three and six months ended December 31, 2019 and 2018, is presented on the same basis as the financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 (the “Annual Report”), filed with the Securities and Exchange Commission on August 27, 2019 (File no. 001-36410). In the opinion of management, these financial statements include all adjustments necessary for a fair statement of the financial position, results of operations and cash flows of the Company for the interim periods, and the adjustments are of a normal and recurring nature. The financial results for any interim period are not necessarily indicative of the results for the full year. The consolidated balance sheet information as of June 30, 2019, was derived from the audited consolidated financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). The unaudited consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report.
The consolidated financial statements include the accounts of Phibro and its consolidated subsidiaries. Intercompany balances and transactions have been eliminated from the consolidated financial statements. The decision whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective control over the entity.
2.
Summary of Significant Accounting Policies and New Accounting Standards
​
Our significant accounting policies are described in the notes to the consolidated financial statements included in our Annual Report. We adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), effective July 1, 2019. See “New Accounting Standards” and “Note 7—Leases.” As of December 31, 2019, there have been no other material changes to our significant accounting policies.
Leases
We determine at the inception of an arrangement whether the arrangement contains a lease. If an arrangement contains a lease, we assess the lease term when the underlying asset is available for use (“lease commencement.”) Individual lease terms reflect the non-cancellable period of the lease, reasonably certain renewal periods and consideration of termination options. We determine the lease classification as either operating or financing at lease commencement, which governs the pattern of expense recognition and presentation in our consolidated financial statements. Our current lease portfolio only includes operating leases.
We recognize a right-of-use (“ROU”) asset and a corresponding lease liability at lease commencement for leases with terms exceeding twelve months. Short-term leases with terms of twelve months or less are not recognized on the consolidated balance sheet and lease payments are recognized on a straight-line basis over the term.
The values of the ROU assets and lease liabilities are calculated based on the present value of the fixed payment obligations over the lease term, using our incremental borrowing rate (“IBR”), determined at lease commencement. The IBR reflects the rate of interest we would expect to pay on a secured basis to borrow an amount equal to the lease payments under similar terms. The IBR incorporates the term and economic environment of the respective lease arrangements.
8

TABLE OF CONTENTS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
We have elected to account for lease and non-lease components together as a single lease component and include fixed payment obligations related to such non-lease components in the measurement of ROU assets and lease liabilities. Fixed lease payments are recognized on a straight-line basis over the lease term. Variable lease payments can include index-based lease payments, real estate taxes, maintenance costs, utilization charges and other non-lease services paid to lessors and are not determinable at lease commencement. Variable lease payments are not included in the measurement of ROU assets and lease liabilities and are recognized in the period incurred.
Net Income per Share and Weighted Average Shares
Basic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period.
Diluted net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period after giving effect to potential dilutive common shares resulting from the assumed exercise of stock options and vesting of restricted stock units. All common share equivalents were included in the calculation of diluted net income per share in the periods included in the consolidated financial statements.

​ | ​ | ​ | Three Months | ​ | ​ | Six Months | ​
For the Periods Ended December 31 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​
Net income | ​ | ​ | ​ | $ | 11,894 | ​ | ​ | ​ | ​ | $ | 14,748 | ​ | ​ | ​ | ​ | $ | 14,409 | ​ | ​ | ​ | ​ | $ | 31,062 | ​ | ​
Weighted average number of shares – basic | ​ | ​ | ​ | ​ | 40,454 | ​ | ​ | ​ | ​ | ​ | 40,383 | ​ | ​ | ​ | ​ | ​ | 40,454 | ​ | ​ | ​ | ​ | ​ | 40,376 | ​ | ​
Dilutive effect of stock options and restricted stock units | ​ | ​ | ​ | ​ | 50 | ​ | ​ | ​ | ​ | ​ | 140 | ​ | ​ | ​ | ​ | ​ | 50 | ​ | ​ | ​ | ​ | ​ | 147 | ​ | ​
Weighted average number of shares – diluted | ​ | ​ | ​ | ​ | 40,504 | ​ | ​ | ​ | ​ | ​ | 40,523 | ​ | ​ | ​ | ​ | ​ | 40,504 | ​ | ​ | ​ | ​ | ​ | 40,523 | ​ | ​
Net income per share | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
basic | ​ | ​ | ​ | $ | 0.29 | ​ | ​ | ​ | ​ | $ | 0.37 | ​ | ​ | ​ | ​ | $ | 0.36 | ​ | ​ | ​ | ​ | $ | 0.77 | ​ | ​
diluted | ​ | ​ | ​ | $ | 0.29 | ​ | ​ | ​ | ​ | $ | 0.36 | ​ | ​ | ​ | ​ | $ | 0.36 | ​ | ​ | ​ | ​ | $ | 0.77 | ​ | ​

New Accounting Standards
ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, removes certain exceptions and amends certain requirements in the existing income tax guidance to ease accounting requirements. This ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and must be applied on a retrospective basis. We continue to evaluate the effect of adoption of this guidance on our consolidated financial statements.
ASU 2018-14, Compensation—Retirement Benefits—Defined Benefit Plans—General
(Topic 715-20): Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans, modifies existing disclosure requirements for defined benefit pension and other postretirement plans. This ASU is effective for fiscal years ending after December 15, 2020 and must be applied on a retrospective basis. We continue to evaluate the effect of adoption of this guidance on our consolidated financial statements.
ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, modifies existing disclosure requirements for fair value measurement. This ASU is effective for fiscal years beginning after December 15, 2019. We continue to evaluate the effect of adoption of this guidance on our consolidated financial statements.
ASU 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income allows reclassification from accumulated other comprehensive income to retained earnings of stranded tax effects related to adjustments resulting from the United States Tax Cuts and Jobs Act. This ASU is effective for our consolidated financial statements beginning July 1, 2019. The adoption of this guidance did not have a material effect on our consolidated financial statements.
9

TABLE OF CONTENTS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
ASU 2016-02, Leases (Topic 842) requires an entity to recognize assets and liabilities on the balance sheet for both financing and operating leases and requires additional qualitative and quantitative disclosures regarding leasing arrangements. We adopted ASU 2016-02 and its amendments effective July 1, 2019, using a modified retrospective transition approach, which does not require modifications to periods prior to the date of initial application. We utilized certain permitted practical expedients intended to ease transition to the new standard, including carrying forward the original lease classifications without reassessment. We did not use hindsight in our assessment of lease terms as of the effective date. Upon adoption of ASU 2016-02 on July 1, 2019, we recognized initial ROU assets and lease liabilities of   $18,576 and $19,368 respectively, on the consolidated balance sheet. The difference in the amounts of the ROU assets and lease liabilities recognized relates to landlord incentives and deferred rent. An adjustment to opening retained earnings was not required, and the recognition of lease expense in the consolidated statements of operations did not change significantly. Refer to “Note 7—Leases” for further information.
3.
Acquisition
​
In August 2019, we acquired the business and assets of Osprey Biotechnics, Inc. (“Osprey”). Osprey is a developer, manufacturer and marketer of microbial products and bioproducts for a variety of applications, serving customers in the animal health and nutrition, environmental, industrial and plant protection industries. The business is included in the Animal Health segment.
We acquired assets used in Osprey’s business, including intellectual property, working capital and property, plant and equipment, for an aggregate net cash payment of  $54,549. The agreement also includes a future additional payment to be determined based on Osprey’s financial performance for the year ending June 30, 2021. We recorded a $7,553 liability for the estimated future payment. The additional payment will be no less than $4,840 and has no maximum limit.
We accounted for the acquisition as a business combination in accordance with FASB Accounting Standards Codification No. 805, Business Combinations. Pro forma information giving effect to the acquisition has not been provided because the results are not material to the consolidated financial statements. The preliminary fair values of the acquired assets and liabilities as of the acquisition date were:

​ | Working capital, net | ​ | ​ | ​ | $ | 2,366 | ​ | ​
​ | Property, plant and equipment | ​ | ​ | ​ | ​ | 2,005 | ​ | ​
​ | Definite-lived intangible assets | ​ | ​ | ​ | ​ | 32,400 | ​ | ​
​ | Goodwill | ​ | ​ | ​ | ​ | 25,331 | ​ | ​
​ | Net assets acquired | ​ | ​ | ​ | $ | 62,102 | ​ | ​

We may further refine the determination of certain assets during the measurement period. The definite-lived intangible assets relate to trade names, developed products and customer relationships and will be amortized over estimated useful lives ranging from five to twelve years. The preliminary amount of goodwill has been allocated to our Animal Health segment and is deductible for income taxes.
4.
Statements of Operations—Additional Information
​
We develop, manufacture and market a broad range of products for food animals including poultry, swine, beef and dairy cattle and aquaculture. The products help prevent, control and treat diseases, enhance nutrition to help improve health and contribute to balanced mineral nutrition. The animal health and mineral nutrition products are sold directly to integrated poultry, swine and cattle integrators and through commercial animal feed manufacturers, wholesalers and distributors. The animal health industry and demand for many of the animal health products in a particular region are affected by changing disease pressures and by weather conditions, as product usage follows varying weather patterns and seasons. Our operations are primarily focused in regions where the majority of livestock production is consolidated in large commercial farms.
We have a diversified portfolio of products that are classified within our three business segments—Animal Health, Mineral Nutrition and Performance Products. Each segment has its own dedicated management and sales team.
10

TABLE OF CONTENTS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Animal Health
The Animal Health business develops, manufactures and markets products in three main categories:
•
MFAs and Other: MFAs and other products primarily consist of concentrated medicated products that are administered through animal feeds, commonly referred to as Medicated Feed Additives (“MFAs”). Specific product classifications include antibacterials, which inhibit the growth of pathogenic bacteria that cause bacterial infections in animals; anticoccidials, which inhibit the growth of coccidia (parasites) that damage the intestinal tract of animals; and other related products.
​
•
Nutritional Specialties: Nutritional specialty products enhance nutrition to help improve health and performance in areas such as immune system function and digestive health.
​
•
Vaccines: Our vaccines are primarily focused on preventing diseases in poultry, swine and cattle. They protect animals from either viral or bacterial disease challenges. We develop, manufacture and market conventionally licensed and autogenous vaccine products and also produce and market adjuvants to vaccine manufacturers. We have developed and market an innovative and proprietary delivery platform for vaccines.
​
Mineral Nutrition
The Mineral Nutrition business is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The customers use these products to fortify the daily feed requirements of their livestock’s diets and maintain an optimal balance of trace elements in each animal. We manufacture and market a broad range of mineral nutrition products for food animals including poultry, swine and beef and dairy cattle.
Performance Products
The Performance Products business manufactures and markets a number of specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries, predominantly in the United States.
The following tables present our revenues disaggregated by major product category and geographic region:
Net Sales by Product Type

​ | ​ | ​ | Three Months | ​ | ​ | Six Months | ​
For the Periods Ended December 31 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​
Animal Health | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
MFAs and other | ​ | ​ | ​ | $ | 91,955 | ​ | ​ | ​ | ​ | $ | 93,054 | ​ | ​ | ​ | ​ | $ | 166,989 | ​ | ​ | ​ | ​ | $ | 180,058 | ​ | ​
Nutritional specialties | ​ | ​ | ​ | ​ | 33,062 | ​ | ​ | ​ | ​ | ​ | 29,460 | ​ | ​ | ​ | ​ | ​ | 63,495 | ​ | ​ | ​ | ​ | ​ | 56,430 | ​ | ​
Vaccines | ​ | ​ | ​ | ​ | 18,672 | ​ | ​ | ​ | ​ | ​ | 17,048 | ​ | ​ | ​ | ​ | ​ | 35,055 | ​ | ​ | ​ | ​ | ​ | 34,263 | ​ | ​
Total Animal Health | ​ | ​ | ​ | $ | 143,689 | ​ | ​ | ​ | ​ | $ | 139,562 | ​ | ​ | ​ | ​ | $ | 265,539 | ​ | ​ | ​ | ​ | $ | 270,751 | ​ | ​
Mineral Nutrition | ​ | ​ | ​ | ​ | 55,685 | ​ | ​ | ​ | ​ | ​ | 62,319 | ​ | ​ | ​ | ​ | ​ | 108,334 | ​ | ​ | ​ | ​ | ​ | 117,157 | ​ | ​
Performance Products | ​ | ​ | ​ | ​ | 14,638 | ​ | ​ | ​ | ​ | ​ | 16,342 | ​ | ​ | ​ | ​ | ​ | 29,859 | ​ | ​ | ​ | ​ | ​ | 30,468 | ​ | ​
Total | ​ | ​ | ​ | $ | 214,012 | ​ | ​ | ​ | ​ | $ | 218,223 | ​ | ​ | ​ | ​ | $ | 403,732 | ​ | ​ | ​ | ​ | $ | 418,376 | ​ | ​

Net Sales by Region

​ | ​ | ​ | Three Months | ​ | ​ | Six Months | ​
For the Periods Ended December 31 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​
United States | ​ | ​ | ​ | $ | 122,917 | ​ | ​ | ​ | ​ | $ | 126,065 | ​ | ​ | ​ | ​ | $ | 241,404 | ​ | ​ | ​ | ​ | $ | 240,552 | ​ | ​
Latin America and Canada | ​ | ​ | ​ | ​ | 42,704 | ​ | ​ | ​ | ​ | ​ | 40,273 | ​ | ​ | ​ | ​ | ​ | 79,445 | ​ | ​ | ​ | ​ | ​ | 79,156 | ​ | ​
Europe, Middle East and Africa | ​ | ​ | ​ | ​ | 27,660 | ​ | ​ | ​ | ​ | ​ | 26,186 | ​ | ​ | ​ | ​ | ​ | 51,353 | ​ | ​ | ​ | ​ | ​ | 51,022 | ​ | ​
Asia Pacific | ​ | ​ | ​ | ​ | 20,731 | ​ | ​ | ​ | ​ | ​ | 25,699 | ​ | ​ | ​ | ​ | ​ | 31,530 | ​ | ​ | ​ | ​ | ​ | 47,646 | ​ | ​
Total | ​ | ​ | ​ | $ | 214,012 | ​ | ​ | ​ | ​ | $ | 218,223 | ​ | ​ | ​ | ​ | $ | 403,732 | ​ | ​ | ​ | ​ | $ | 418,376 | ​ | ​
​

11

TABLE OF CONTENTS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Net sales by region are based on country of destination.
Deferred revenue was $5,130 and $5,464 as of December 31, 2019 and June 30, 2019, respectively. Accrued expenses and other current liabilities included $1,082 and $965 of the total deferred revenue as of December 31, 2019 and June 30, 2019, respectively. The deferred revenue resulted primarily from certain customer arrangements, including technology licensing fees and discounts on future product sales. The transaction price associated with our deferred revenue arrangements is generally based on the stand alone sales prices of the individual products or services.
Our customer payment terms generally range from 30 to 120 days globally and do not include any significant financing components. Payment terms vary based on industry and business practices within the regions in which we operate. Our average worldwide collection period for accounts receivable is approximately 60 to 70 days after the revenue is recognized.
Interest Expense and Depreciation and Amortization

​ | ​ | ​ | Three Months | ​ | ​ | Six Months | ​
For the Periods Ended December 31 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​
Interest expense, net | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Term loan | ​ | ​ | ​ | $ | 2,031 | ​ | ​ | ​ | ​ | $ | 2,202 | ​ | ​ | ​ | ​ | $ | 4,079 | ​ | ​ | ​ | ​ | $ | 4,314 | ​ | ​
Revolving credit facility | ​ | ​ | ​ | ​ | 1,530 | ​ | ​ | ​ | ​ | ​ | 920 | ​ | ​ | ​ | ​ | ​ | 2,961 | ​ | ​ | ​ | ​ | ​ | 1,667 | ​ | ​
Amortization of debt issuance costs and debt discount | ​ | ​ | ​ | ​ | 221 | ​ | ​ | ​ | ​ | ​ | 220 | ​ | ​ | ​ | ​ | ​ | 442 | ​ | ​ | ​ | ​ | ​ | 441 | ​ | ​
Acquisition-related accrued interest | ​ | ​ | ​ | ​ | 79 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 132 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​
Other | ​ | ​ | ​ | ​ | 76 | ​ | ​ | ​ | ​ | ​ | 120 | ​ | ​ | ​ | ​ | ​ | 156 | ​ | ​ | ​ | ​ | ​ | 283 | ​ | ​
Interest expense | ​ | ​ | ​ | ​ | 3,937 | ​ | ​ | ​ | ​ | ​ | 3,462 | ​ | ​ | ​ | ​ | ​ | 7,770 | ​ | ​ | ​ | ​ | ​ | 6,705 | ​ | ​
Interest (income) | ​ | ​ | ​ | ​ | (505) | ​ | ​ | ​ | ​ | ​ | (447) | ​ | ​ | ​ | ​ | ​ | (984) | ​ | ​ | ​ | ​ | ​ | (907) | ​ | ​
​ | ​ | ​ | ​ | $ | 3,432 | ​ | ​ | ​ | ​ | $ | 3,015 | ​ | ​ | ​ | ​ | $ | 6,786 | ​ | ​ | ​ | ​ | $ | 5,798 | ​ | ​
​

​ | ​ | ​ | Three Months | ​ | ​ | Six Months | ​
For the Periods Ended December 31 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​
Depreciation and amortization | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Depreciation of property, plant and equipment | ​ | ​ | ​ | $ | 5,840 | ​ | ​ | ​ | ​ | $ | 5,308 | ​ | ​ | ​ | ​ | $ | 11,571 | ​ | ​ | ​ | ​ | $ | 10,496 | ​ | ​
Amortization of intangible assets | ​ | ​ | ​ | ​ | 2,296 | ​ | ​ | ​ | ​ | ​ | 1,521 | ​ | ​ | ​ | ​ | ​ | 4,334 | ​ | ​ | ​ | ​ | ​ | 3,012 | ​ | ​
Amortization of other assets | ​ | ​ | ​ | ​ | 12 | ​ | ​ | ​ | ​ | ​ | 12 | ​ | ​ | ​ | ​ | ​ | 24 | ​ | ​ | ​ | ​ | ​ | 24 | ​ | ​
​ | ​ | ​ | ​ | $ | 8,148 | ​ | ​ | ​ | ​ | $ | 6,841 | ​ | ​ | ​ | ​ | $ | 15,929 | ​ | ​ | ​ | ​ | $ | 13,532 | ​ | ​

5.
Balance Sheets—Additional Information
​

As of | ​ | ​ | December 31, 2019 | ​ | ​ | June 30, 2019 | ​
Inventories | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Raw materials | ​ | ​ | ​ | $ | 73,394 | ​ | ​ | ​ | ​ | $ | 64,441 | ​ | ​
Work-in-process | ​ | ​ | ​ | ​ | 10,489 | ​ | ​ | ​ | ​ | ​ | 10,699 | ​ | ​
Finished goods | ​ | ​ | ​ | ​ | 109,626 | ​ | ​ | ​ | ​ | ​ | 123,182 | ​ | ​
​ | ​ | ​ | ​ | $ | 193,509 | ​ | ​ | ​ | ​ | $ | 198,322 | ​ | ​
​

As of | ​ | ​ | December 31, 2019 | ​ | ​ | June 30, 2019 | ​
Goodwill roll-forward | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Balance at beginning of period | ​ | ​ | ​ | $ | 27,348 | ​ | ​ | ​ | ​ | $ | 27,348 | ​ | ​
Osprey acquisition | ​ | ​ | ​ | ​ | 25,331 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​
Balance at end of period | ​ | ​ | ​ | $ | 52,679 | ​ | ​ | ​ | ​ | $ | 27,348 | ​ | ​
​

12

TABLE OF CONTENTS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
We evaluate our investments in equity method investees for impairment if circumstances indicate that the fair value of the investment may be impaired. The assets underlying a $3,548 equity investment are currently idled; we have concluded the investment is not currently impaired, based on expected future operating cash flows and/or disposal value.

As of | ​ | ​ | December 31, 2019 | ​ | ​ | June 30, 2019 | ​
Other assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
ROU operating lease assets | ​ | ​ | ​ | $ | 23,115 | ​ | ​ | ​ | ​ | $ | — | ​ | ​
Deferred income taxes | ​ | ​ | ​ | ​ | 17,039 | ​ | ​ | ​ | ​ | ​ | 16,770 | ​ | ​
Deposits | ​ | ​ | ​ | ​ | 6,809 | ​ | ​ | ​ | ​ | ​ | 7,024 | ​ | ​
Insurance investments | ​ | ​ | ​ | ​ | 5,521 | ​ | ​ | ​ | ​ | ​ | 5,431 | ​ | ​
Equity method investments | ​ | ​ | ​ | ​ | 4,902 | ​ | ​ | ​ | ​ | ​ | 4,196 | ​ | ​
Indemnification asset | ​ | ​ | ​ | ​ | 3,000 | ​ | ​ | ​ | ​ | ​ | 3,000 | ​ | ​
Deferred financing fees | ​ | ​ | ​ | ​ | 1,276 | ​ | ​ | ​ | ​ | ​ | 1,531 | ​ | ​
Other | ​ | ​ | ​ | ​ | 8,216 | ​ | ​ | ​ | ​ | ​ | 7,496 | ​ | ​
​ | ​ | ​ | ​ | $ | 69,878 | ​ | ​ | ​ | ​ | $ | 45,448 | ​ | ​
​

As of | ​ | ​ | December 31, 2019 | ​ | ​ | June 30, 2019 | ​
Accrued expenses and other current liabilities | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Employee related | ​ | ​ | ​ | $ | 29,845 | ​ | ​ | ​ | ​ | $ | 28,298 | ​ | ​
Current operating lease liabilities | ​ | ​ | ​ | ​ | 6,672 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​
Commissions and rebates | ​ | ​ | ​ | ​ | 7,942 | ​ | ​ | ​ | ​ | ​ | 8,397 | ​ | ​
Insurance-related | ​ | ​ | ​ | ​ | 1,291 | ​ | ​ | ​ | ​ | ​ | 1,279 | ​ | ​
Professional fees | ​ | ​ | ​ | ​ | 5,222 | ​ | ​ | ​ | ​ | ​ | 5,212 | ​ | ​
Income and other taxes | ​ | ​ | ​ | ​ | 4,791 | ​ | ​ | ​ | ​ | ​ | 6,067 | ​ | ​
Restructuring costs | ​ | ​ | ​ | ​ | 2,568 | ​ | ​ | ​ | ​ | ​ | 3,590 | ​ | ​
Other | ​ | ​ | ​ | ​ | 14,840 | ​ | ​ | ​ | ​ | ​ | 15,655 | ​ | ​
​ | ​ | ​ | ​ | $ | 73,171 | ​ | ​ | ​ | ​ | $ | 68,498 | ​ | ​

During the three months ended June 30, 2019, we initiated business restructuring activities related to productivity and cost saving initiatives in the Animal Health segment. We recorded pre-tax charges of $6,281 for these activities, including $3,500 related to the termination of a contract manufacturing agreement and $2,781 for employee separation charges. As of June 30, 2019, $691 had been paid.
During the three months ended September 30, 2019, we recorded $425 related to employee separation charges. The charges are included in selling, general and administrative expenses in our consolidated statements of operations. The following table summarizes the activity of the restructuring liability during the six months ended December 31, 2019:

​ | Liability balance at June 30, 2019 | ​ | ​ | ​ | $ | 5,590 | ​ | ​
​ | Charges | ​ | ​ | ​ | ​ | 425 | ​ | ​
​ | Payments | ​ | ​ | ​ | ​ | (1,847) | ​ | ​
​ | Liability balance at December 31, 2019 | ​ | ​ | ​ | $ | 4,168 | ​ | ​

As of December 31, 2019, $2,568 was included in accrued expenses and other current liabilities and $1,600 was included in other liabilities. We expect to record an additional charge for employee separation costs of an estimated $500 and plan to complete the additional separation actions by June 30, 2020.
13

TABLE OF CONTENTS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

As of | ​ | ​ | December 31, 2019 | ​ | ​ | June 30, 2019 | ​
Other liabilities | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Long-term operating lease liabilities | ​ | ​ | ​ | $ | 17,453 | ​ | ​ | ​ | ​ | $ | — | ​ | ​
Long term and deferred income taxes | ​ | ​ | ​ | ​ | 9,520 | ​ | ​ | ​ | ​ | ​ | 8,978 | ​ | ​
Supplemental retirement benefits, deferred compensation and other | ​ | ​ | ​ | ​ | 7,837 | ​ | ​ | ​ | ​ | ​ | 7,605 | ​ | ​
Acquisition-related consideration | ​ | ​ | ​ | ​ | 7,678 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​
International retirement plans | ​ | ​ | ​ | ​ | 5,247 | ​ | ​ | ​ | ​ | ​ | 5,133 | ​ | ​
U.S. pension plan | ​ | ​ | ​ | ​ | 3,146 | ​ | ​ | ​ | ​ | ​ | 3,934 | ​ | ​
Restructuring costs | ​ | ​ | ​ | ​ | 1,600 | ​ | ​ | ​ | ​ | ​ | 2,000 | ​ | ​
Other long term liabilities | ​ | ​ | ​ | ​ | 13,917 | ​ | ​ | ​ | ​ | ​ | 15,144 | ​ | ​
​ | ​ | ​ | ​ | $ | 66,398 | ​ | ​ | ​ | ​ | $ | 42,794 | ​ | ​
​

As of | ​ | ​ | December 31, 2019 | ​ | ​ | June 30, 2019 | ​
Accumulated other comprehensive income (loss) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Derivative instruments | ​ | ​ | ​ | $ | (598) | ​ | ​ | ​ | ​ | $ | (594) | ​ | ​
Foreign currency translation adjustment | ​ | ​ | ​ | ​ | (75,845) | ​ | ​ | ​ | ​ | ​ | (71,225) | ​ | ​
Unrecognized net pension gains (losses) | ​ | ​ | ​ | ​ | (19,792) | ​ | ​ | ​ | ​ | ​ | (20,050) | ​ | ​
(Provision) benefit for income taxes on derivative instruments | ​ | ​ | ​ | ​ | 149 | ​ | ​ | ​ | ​ | ​ | 148 | ​ | ​
(Provision) benefit for incomes taxes on long-term intercompany investments | ​ | ​ | ​ | ​ | 8,166 | ​ | ​ | ​ | ​ | ​ | 8,166 | ​ | ​
(Provision) benefit for income taxes on pension gains (losses) | ​ | ​ | ​ | ​ | (2,690) | ​ | ​ | ​ | ​ | ​ | (2,626) | ​ | ​
​ | ​ | ​ | ​ | $ | (90,610) | ​ | ​ | ​ | ​ | $ | (86,181) | ​ | ​

6.
Debt
​
Term Loans and Revolving Credit Facilities
Pursuant to a credit agreement (the “Credit Agreement”), we have a revolving credit facility (the “Revolver”), where we can borrow up to $250,000, subject to the terms of the agreement, and a term A loan with an aggregate initial principal amount of  $250,000 (the “Term A Loan,” and together with the Revolver, the “Credit Facilities”). The Credit Facilities have applicable margins equal to 2.00%, 1.75% or 1.50%, in the case of LIBOR and Eurodollar rate loans and 1.00%, 0.75% or 0.50%, in the case of base rate loans; the applicable margins are based on the First Lien Net Leverage Ratio, as defined in the Credit Agreement. The LIBOR rate is subject to a floor of 0.00%. The Credit Facilities mature on June 29, 2022.
The Credit Facilities require, among other things, the maintenance of  (i) a maximum First Lien Net Leverage Ratio and (ii) a minimum consolidated interest coverage ratio, each calculated on a trailing four quarter basis, and contain an acceleration clause should an event of default (as defined in the Credit Agreement) occur. As of December 31, 2019, we were in compliance with the financial covenants.
As of December 31, 2019, we had $149,000 in borrowings under the Revolver and had outstanding letters of credit of  $2,709, leaving $98,291 available for borrowings and letters of credit under the Revolver. We obtain letters of credit in connection with certain regulatory and insurance obligations, inventory purchases and other contractual obligations. The terms of these letters of credit are all less than one year.
As of December 31, 2019, the interest rates for the Revolver and the Term A Loan were 3.51% and 3.61%, respectively. The weighted-average interest rates for the outstanding revolving credit facilities were 3.58% and 3.71% for the six months ended December 31, 2019 and 2018, respectively. The weighted-average interest rates for the term loans were 3.46% and 3.47% for the six months ended December 31, 2019 and 2018, respectively.
14

TABLE OF CONTENTS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
In July 2017, we entered into an interest rate swap agreement on $150,000 of notional principal that effectively converts the floating LIBOR portion of our interest obligation on that amount of debt, to a fixed interest rate of 1.8325% plus the applicable rate. The agreement matures concurrent with the Credit Agreement. We designated the interest rate swap as a highly effective cash flow hedge. For additional details, see “—Derivatives.”
Long-Term Debt

As of | ​ | ​ | December 31, 2019 | ​ | ​ | June 30, 2019 | ​
Term A Loan due June 2022 | ​ | ​ | ​ | $ | 225,000 | ​ | ​ | ​ | ​ | $ | 231,250 | ​ | ​
Other | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 40 | ​ | ​
​ | ​ | ​ | ​ | ​ | 225,000 | ​ | ​ | ​ | ​ | ​ | 231,290 | ​ | ​
Unamortized debt issuance costs and debt discount | ​ | ​ | ​ | ​ | (929) | ​ | ​ | ​ | ​ | ​ | (1,115) | ​ | ​
​ | ​ | ​ | ​ | ​ | 224,071 | ​ | ​ | ​ | ​ | ​ | 230,175 | ​ | ​
Less: current maturities | ​ | ​ | ​ | ​ | (15,625) | ​ | ​ | ​ | ​ | ​ | (12,540) | ​ | ​
​ | ​ | ​ | ​ | $ | 208,446 | ​ | ​ | ​ | ​ | $ | 217,635 | ​ | ​

7.
Leases
​
Our lease portfolio consists of real estate, vehicles and equipment ROU assets, classified as operating leases. As of December 31, 2019, the remaining non-cancelable lease terms, inclusive of renewal options reasonably certain of exercise, range from one to 16 years.
The following table summarizes the ROU assets and the related lease liabilities recorded on the consolidated balance sheet:

As of | ​ | ​ | December 31, 2019 | ​ | ​ | Balance Sheet Classification | ​
Assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating lease ROU assets | ​ | ​ | ​ | $ | 23,115 | ​ | ​ | ​ | Other Assets | ​
Liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Current portion | ​ | ​ | ​ | ​ | 6,672 | ​ | ​ | ​ | Accrued expenses and other current liabilities | ​
Non-current portion | ​ | ​ | ​ | ​ | 17,453 | ​ | ​ | ​ | Other liabilities | ​
Total operating lease liabilities | ​ | ​ | ​ | $ | 24,125 | ​ | ​ | ​ | ​ | ​

The following table summarizes the composition of net lease cost:

For the Periods Ended December 31 | ​ | ​ | Three months 2019 | ​ | ​ | Six months 2019 | ​
Operating lease expense | ​ | ​ | ​ | $ | 1,911 | ​ | ​ | ​ | ​ | $ | 3,762 | ​ | ​
Variable lease expense | ​ | ​ | ​ | ​ | 307 | ​ | ​ | ​ | ​ | ​ | 631 | ​ | ​
Short-term lease expense | ​ | ​ | ​ | ​ | 214 | ​ | ​ | ​ | ​ | ​ | 417 | ​ | ​
Total lease cost | ​ | ​ | ​ | $ | 2,432 | ​ | ​ | ​ | ​ | $ | 4,810 | ​ | ​

The following tables include other supplemental information:

For the Periods Ended December 31 | ​ | ​ | Three months 2019 | ​ | ​ | Six months 2019 | ​
Operating cash flows used for ROU operating leases | ​ | ​ | ​ | $ | 1,968 | ​ | ​ | ​ | ​ | $ | 3,645 | ​ | ​
Right of use assets obtained in exchange for new operating lease liabilities | ​ | ​ | ​ | $ | 3,972 | ​ | ​ | ​ | ​ | $ | 7,762 | ​ | ​

15

TABLE OF CONTENTS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

​ | ​ | ​ | As of December 31, 2019 | ​
Weighted average remaining lease term (in years) – ROU operating leases | ​ | ​ | ​ | ​ | 6.4 | ​ | ​
Weighted average discount rate – ROU operating leases | ​ | ​ | ​ | ​ | 4.17% | ​ | ​

At December 31, 2019, maturities of future lease liabilities were:

For the Years Ending June 30 | ​ | ​ | ​ | ​ | ​ | ​ | ​
2020 | ​ | ​ | ​ | $ | 3,853 | ​ | ​
2021 | ​ | ​ | ​ | ​ | 6,627 | ​ | ​
2022 | ​ | ​ | ​ | ​ | 5,012 | ​ | ​
2023 | ​ | ​ | ​ | ​ | 2,765 | ​ | ​
2024 | ​ | ​ | ​ | ​ | 2,283 | ​ | ​
2025 and thereafter | ​ | ​ | ​ | ​ | 7,273 | ​ | ​
Total lease payments | ​ | ​ | ​ | ​ | 27,813 | ​ | ​
Less: interest | ​ | ​ | ​ | ​ | 3,688 | ​ | ​
Total operating lease liabilities | ​ | ​ | ​ | $ | 24,125 | ​ | ​

There were no significant future payment obligations related to executed lease agreements for which the related lease had not yet commenced as of December 31, 2019. Our lease agreements do not contain any material restrictive covenants or residual value guarantee provisions.
Future minimum lease payments for operating leases accounted for under ASC 840, “Leases,” with remaining non-cancelable terms in excess of one year at June 30, 2019 were:

For the Years Ending June 30 | ​ | ​ | ​ | ​ | ​ | ​ | ​
2020 | ​ | ​ | ​ | $ | 5,815 | ​ | ​
2021 | ​ | ​ | ​ | ​ | 4,160 | ​ | ​
2022 | ​ | ​ | ​ | ​ | 3,191 | ​ | ​
2023 | ​ | ​ | ​ | ​ | 1,445 | ​ | ​
2024 | ​ | ​ | ​ | ​ | 865 | ​ | ​
Thereafter | ​ | ​ | ​ | ​ | 765 | ​ | ​
Total minimum lease payments | ​ | ​ | ​ | $ | 16,241 | ​ | ​

8.
Related Party Transactions
​
Certain relatives of Jack C. Bendheim, our Chairman, President and Chief Executive Officer, provided services to us as employees or consultants and received aggregate compensation and benefits of approximately $390 and $430 during the three months ended December 31, 2019 and 2018, respectively, and $841 and $1,213 during the six months ended December 31, 2019 and 2018, respectively. Mr. Bendheim has sole authority to vote shares of our stock owned by BFI Co., LLC, an investment vehicle of the Bendheim family.
9.
Commitments and Contingencies
​
Environmental
Our operations and properties are subject to extensive federal, state, local and foreign laws and regulations, including those governing pollution; protection of the environment; the use, management, and release of hazardous materials, substances and wastes; air emissions; greenhouse gas emissions; water use, supply and discharges; the investigation and remediation of contamination; the manufacture, distribution, and sale of regulated materials, including pesticides; the importing, exporting and transportation of products; and the health and safety of our employees (collectively, “Environmental Laws”). As such, the nature of our current and former operations exposes us to the risk of claims with respect to such matters, including fines, penalties, and remediation obligations that may be imposed by regulatory authorities.
16

TABLE OF CONTENTS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Under certain circumstances, we might be required to curtail operations until a particular problem is remedied. Known costs and expenses under Environmental Laws incidental to ongoing operations, including the cost of litigation proceedings relating to environmental matters, are included within operating results. Potential costs and expenses may also be incurred in connection with the repair or upgrade of facilities to meet existing or new requirements under Environmental Laws or to investigate or remediate potential or actual contamination and from time to time we establish reserves for such contemplated investigation and remediation costs. In many instances, the ultimate costs under Environmental Laws and the time period during which such costs are likely to be incurred are difficult to predict.
While we believe that our operations are currently in material compliance with Environmental Laws, we have, from time to time, received notices of violation from governmental authorities, and have been involved in civil or criminal action for such violations. Additionally, at various sites, our subsidiaries are engaged in continuing investigation, remediation and/or monitoring efforts to address contamination associated with historic operations of the sites. We devote considerable resources to complying with Environmental Laws and managing environmental liabilities. We have developed programs to identify requirements under, and maintain compliance with, Environmental Laws; however, we cannot predict with certainty the effect of increased and more stringent regulation on our operations, future capital expenditure requirements, or the cost of compliance.
The nature of our current and former operations exposes us to the risk of claims with respect to environmental matters and we cannot assure we will not incur material costs and liabilities in connection with such claims. Based upon our experience to date, we believe that the future cost of compliance with existing Environmental Laws, and liabilities for known environmental claims pursuant to such Environmental Laws, will not have a material adverse effect on our financial position, results of operations, cash flows or liquidity.
The United States Environmental Protection Agency (the “EPA”) is investigating and planning for the remediation of offsite contaminated groundwater that has migrated from the Omega Chemical Corporation Superfund Site (“Omega Chemical Site”), which is upgradient of Phibro-Tech’s Santa Fe Springs, California facility. The EPA has named Phibro-Tech and certain other subsidiaries of PAHC as potentially responsible parties (“PRPs”) due to groundwater contamination from Phibro-Tech’s Santa Fe Springs facility that has allegedly commingled with contaminated groundwater from the Omega Chemical Site. In September 2012, the EPA notified approximately 140 PRPs, including Phibro-Tech and the other subsidiaries, that they have been identified as potentially responsible for remedial action for the groundwater plume affected by the Omega Chemical Site and for EPA oversight and response costs. Phibro-Tech contends that any groundwater contamination at its site is localized and due to historical operations that pre-date Phibro-Tech and/or contaminated groundwater that has migrated from upgradient properties. In addition, a successor to a prior owner of the Phibro-Tech site has asserted that PAHC and Phibro-Tech are obligated to provide indemnification for its potential liability and defense costs relating to the groundwater plume affected by the Omega Chemical Site. Phibro-Tech has vigorously contested this position and has asserted that the successor to the prior owner is required to indemnify Phibro-Tech for its potential liability and defense costs. Furthermore, a group of companies that sent chemicals to the Omega Chemical Site for processing and recycling has filed a complaint under CERCLA and RCRA in the United States District Court for the Central District of California against many of the PRPs allegedly associated with the groundwater plume affected by the Omega Chemical Site (including Phibro-Tech) for contribution toward past and future costs associated with the investigation and remediation of the groundwater plume affected by the Omega Chemical Site. Due to the ongoing nature of the EPA’s investigation, the preliminary stage of the ongoing litigation and Phibro-Tech’s dispute with the prior owner’s successor, at this time we cannot predict with any degree of certainty what, if any, liability Phibro-Tech or the other subsidiaries may ultimately have for investigation, remediation and the EPA oversight and response costs associated with the affected groundwater plume.
Based upon information available, to the extent such costs can be estimated with reasonable certainty, we estimated the cost for further investigation and remediation of identified soil and groundwater problems at operating sites, closed sites and third-party sites, and closure costs for closed sites, to be
17

TABLE OF CONTENTS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
approximately $5,096 and $5,890 at December 31, 2019 and June 30, 2019, respectively, which is included in current and long-term liabilities on the consolidated balance sheets. However, future events, such as new information, changes in existing Environmental Laws or their interpretation, and more vigorous enforcement policies of regulatory agencies, may give rise to additional expenditures or liabilities that could be material. For all purposes of the discussion under this caption and elsewhere in this report, it should be noted that we take and have taken the position that neither PAHC nor any of our subsidiaries is liable for environmental or other claims made against one or more of our other subsidiaries or for which any of such other subsidiaries may ultimately be responsible.
Claims and Litigation
PAHC and its subsidiaries are party to a number of claims and lawsuits arising out of the normal course of business including product liabilities, payment disputes and governmental regulation. Certain of these actions seek damages in various amounts. In many cases, such claims are covered by insurance. We believe that none of the claims or pending lawsuits, either individually or in the aggregate, will have a material adverse effect on our financial position, results of operations, cash flows or liquidity.
10.
Derivatives
​
We monitor our exposure to foreign currency exchange rates and interest rates and from time-to-time use derivatives to manage certain of these risks. We designate derivatives as a hedge of a forecasted transaction or of the variability of the cash flows to be received or paid in the future related to a recognized asset or liability (cash flow hedge). All changes in the fair value of a highly effective cash flow hedge are recorded in accumulated other comprehensive income (loss).
We routinely assess whether the derivatives used to hedge transactions are effective. If we determine a derivative ceases to be an effective hedge, we discontinue hedge accounting in the period of the assessment for that derivative, and immediately recognize any unrealized gains or losses related to the fair value of that derivative in the consolidated statements of operations.
We record derivatives at fair value in the consolidated balance sheets. For additional details regarding fair value, see “—Fair Value Measurements.”
We entered into an interest rate swap agreement on $150,000 of notional principal that effectively converts the floating LIBOR portion of our interest obligation on that amount of debt, to a fixed interest rate of 1.8325% plus the applicable rate. The agreement matures concurrent with the Credit Agreement. The forecasted transactions are probable of occurring, and the interest rate swap has been designated as a highly effective cash flow hedge.
We entered into foreign currency option contracts to hedge cash flows related to monthly inventory purchases. The individual option contracts mature monthly through June 2021. The forecasted inventory purchases are probable of occurring and the individual option contracts were designated as highly effective cash flow hedges.
Outstanding derivatives that are designated and effective as cash flow hedges as of December 31, 2019 were:

Instrument | ​ | ​ | Hedge | ​ | ​ | Notional Amount at December 31, 2019 | ​ | ​ | Consolidated Balance Sheet | ​ | ​ | Asset (Liability) fair value as of | ​
​ | December 31, 2019 | ​ | ​ | June 30, 2019 | ​
Options | ​ | ​ | Brazilian Real calls | ​ | ​ | R$108,000 | ​ | ​ | (1) | ​ | ​ | ​ | $ | 659 | ​ | ​ | ​ | ​ | $ | 413 | ​ | ​
Options | ​ | ​ | Brazilian Real puts | ​ | ​ | R$108,000 | ​ | ​ | (1) | ​ | ​ | ​ | $ | (217) | ​ | ​ | ​ | ​ | $ | (30) | ​ | ​
Swap | ​ | ​ | Interest rate swap | ​ | ​ | $150,000 | ​ | ​ | Other liabilities | ​ | ​ | ​ | $ | (1,040) | ​ | ​ | ​ | ​ | $ | (977) | ​ | ​

​
(1)
We record the net fair values of our outstanding foreign currency option contracts within the respective balance sheet line item based on the net financial position and maturity date of the individual contracts as of the balance sheet date. Other current assets as of December 31, 2019 and June 30, 2019, included net fair values of  $442 and $383, respectively.
​
​
18

TABLE OF CONTENTS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
The following tables show the effects of derivatives on the consolidated statements of operations and other comprehensive income for the three and six months ended December 31, 2019 and 2018.

For the Three Months Ended December 31 | ​
​ | ​ | ​ | ​ | ​ | ​ | Gain (Loss) recorded in OCI | ​ | ​ | Gain (Loss) recognized in consolidated statements of operations | ​ | ​ | Consolidated Statement of Operations Line Item Total | ​
Instrument | ​ | ​ | Hedge | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | Consolidated Statement of Operations | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​
Options | ​ | ​ | Brazilian Real calls | ​ | ​ | ​ | $ | 422 | ​ | ​ | ​ | ​ | $ | 513 | ​ | ​ | ​ | Cost of goods sold | ​ | ​ | ​ | $ | (63) | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 144,908 | ​ | ​ | ​ | ​ | $ | 149,579 | ​ | ​
Swap | ​ | ​ | Interest rate swap | ​ | ​ | ​ | $ | 658 | ​ | ​ | ​ | ​ | $ | (2,756) | ​ | ​ | ​ | Interest expense, net | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 3,432 | ​ | ​ | ​ | ​ | $ | 3,015 | ​ | ​

For the Six Months Ended December 31 | ​
​ | ​ | ​ | ​ | ​ | ​ | Gain (Loss) recorded in OCI | ​ | ​ | Gain (Loss) recognized in consolidated statements of operations | ​ | ​ | Consolidated Statement of Operations Line Item Total | ​
Instrument | ​ | ​ | Hedge | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | Consolidated Statement of Operations | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​
Options | ​ | ​ | Brazilian Real calls | ​ | ​ | ​ | $ | 59 | ​ | ​ | ​ | ​ | $ | 404 | ​ | ​ | ​ | Cost of goods sold | ​ | ​ | ​ | $ | (108) | ​ | ​ | ​ | ​ | $ | 1,084 | ​ | ​ | ​ | ​ | $ | 276,965 | ​ | ​ | ​ | ​ | $ | 283,927 | ​ | ​
Swap | ​ | ​ | Interest rate swap | ​ | ​ | ​ | $ | (63) | ​ | ​ | ​ | ​ | $ | (2,106) | ​ | ​ | ​ | Interest expense, net | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 6,786 | ​ | ​ | ​ | ​ | $ | 5,798 | ​ | ​

We recognize gains (losses) related to foreign currency derivatives as a component of cost of goods sold at the time the hedged item is sold.
11.
Fair Value Measurements
​
Short-term investments
As of December 31, 2019, our short-term investments consist of cash deposits held at financial institutions. We consider the carrying amounts of these short-term investments to be representative of their fair value.
Current Assets and Liabilities
We consider the carrying amounts of current assets and current liabilities to be representative of their fair value because of the current nature of these items.
Contingent Consideration on Acquisitions
We determine the fair value of contingent consideration on acquisitions based on contractual terms, our current forecast of performance factors related to the acquired business and an applicable discount rate.
Letters of Credit
We obtain letters of credit in connection with certain regulatory and insurance obligations, inventory purchases and other contractual obligations. The carrying values of these letters of credit are considered to be representative of their fair values because of the nature of the instruments.
Debt
We record debt, including term loans and revolver balances, at book value in our consolidated financial statements. We believe the carrying value of the debt is approximately equal to its fair value, due to the variable nature of the instruments.
Derivatives
We determine the fair value of derivative instruments based upon pricing models using observable market inputs for these types of financial instruments, such as spot and forward currency translation rates.
19

TABLE OF CONTENTS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Non-financial assets
Our non-financial assets, which primarily consist of goodwill, other intangible assets, property and equipment, and lease-related ROU assets, are not required to be measured at fair value on a recurring basis, and instead are reported at carrying value in the consolidated balance sheet. We assess the carrying values of non-financial assets for impairment on a periodic basis or whenever events or changes in circumstances indicate an asset may not be fully recoverable.
Fair Value of Assets (Liabilities)

As of | ​ | ​ | December 31, 2019 | ​ | ​ | June 30, 2019 | ​
​ | ​ | ​ | Level 1 | ​ | ​ | Level 2 | ​ | ​ | Level 3 | ​ | ​ | Level 1 | ​ | ​ | Level 2 | ​ | ​ | Level 3 | ​
Short-term investments | ​ | ​ | ​ | $ | 49,000 | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 24,000 | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​
Foreign currency derivatives | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 442 | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 383 | ​ | ​ | ​ | ​ | $ | — | ​ | ​
Interest rate swap | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | (1,040) | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | (977) | ​ | ​ | ​ | ​ | $ | — | ​ | ​
Contingent consideration on acquisitions | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | (7,678) | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​

The table below provides a summary of the changes in the fair value of Level 3 liabilities:

​ | Balance at June 30, 2019 | ​ | ​ | ​ | $ | — | ​ | ​
​ | Osprey acquisition | ​ | ​ | ​ | ​ | (7,553) | ​ | ​
​ | Acquisition-related accrued interest | ​ | ​ | ​ | ​ | (125) | ​ | ​
​ | Balance at December 31, 2019 | ​ | ​ | ​ | ($ | 7,678) | ​ | ​

12.
Business Segments
​
We evaluate performance and allocate resources based on the Animal Health, Mineral Nutrition and Performance Products segments. Certain of our costs and assets are not directly attributable to these segments and we refer to these items as Corporate. We do not allocate Corporate costs or assets to the segments because they are not used to evaluate the segments’ operating results or financial position. Corporate costs include certain costs related to executive management, business technology, legal, finance, human resources and business development.
We evaluate performance of our segments based on Adjusted EBITDA. We define Adjusted EBITDA as income before income taxes plus (a) interest expense, net, (b) depreciation and amortization, (c) (income) loss from, and disposal of, discontinued operations, (d) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency gains and losses and loss on extinguishment of debt, and (e) certain items that we consider to be unusual, non-operational or non-recurring.
The accounting policies of our segments are the same as those described in the summary of significant accounting policies included herein.

​ | ​ | ​ | Three Months | ​ | ​ | Six Months | ​
For the Periods Ended December 31 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​
Net sales | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Animal Health | ​ | ​ | ​ | $ | 143,689 | ​ | ​ | ​ | ​ | $ | 139,562 | ​ | ​ | ​ | ​ | $ | 265,539 | ​ | ​ | ​ | ​ | $ | 270,751 | ​ | ​
Mineral Nutrition | ​ | ​ | ​ | ​ | 55,685 | ​ | ​ | ​ | ​ | ​ | 62,319 | ​ | ​ | ​ | ​ | ​ | 108,334 | ​ | ​ | ​ | ​ | ​ | 117,157 | ​ | ​
Performance Products | ​ | ​ | ​ | ​ | 14,638 | ​ | ​ | ​ | ​ | ​ | 16,342 | ​ | ​ | ​ | ​ | ​ | 29,859 | ​ | ​ | ​ | ​ | ​ | 30,468 | ​ | ​
Total segments | ​ | ​ | ​ | $ | 214,012 | ​ | ​ | ​ | ​ | $ | 218,223 | ​ | ​ | ​ | ​ | $ | 403,732 | ​ | ​ | ​ | ​ | $ | 418,376 | ​ | ​
Depreciation and amortization | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Animal Health | ​ | ​ | ​ | $ | 6,711 | ​ | ​ | ​ | ​ | $ | 5,493 | ​ | ​ | ​ | ​ | $ | 13,095 | ​ | ​ | ​ | ​ | $ | 10,849 | ​ | ​
Mineral Nutrition | ​ | ​ | ​ | ​ | 629 | ​ | ​ | ​ | ​ | ​ | 616 | ​ | ​ | ​ | ​ | ​ | 1,242 | ​ | ​ | ​ | ​ | ​ | 1,213 | ​ | ​
Performance Products | ​ | ​ | ​ | ​ | 417 | ​ | ​ | ​ | ​ | ​ | 279 | ​ | ​ | ​ | ​ | ​ | 794 | ​ | ​ | ​ | ​ | ​ | 552 | ​ | ​
Total segments | ​ | ​ | ​ | $ | 7,757 | ​ | ​ | ​ | ​ | $ | 6,388 | ​ | ​ | ​ | ​ | $ | 15,131 | ​ | ​ | ​ | ​ | $ | 12,614 | ​ | ​
​

20

TABLE OF CONTENTS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

​ | ​ | ​ | Three Months | ​ | ​ | Six Months | ​
For the Periods Ended December 31 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​
Adjusted EBITDA | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Animal Health | ​ | ​ | ​ | $ | 33,838 | ​ | ​ | ​ | ​ | $ | 35,925 | ​ | ​ | ​ | ​ | $ | 58,899 | ​ | ​ | ​ | ​ | $ | 71,641 | ​ | ​
Mineral Nutrition | ​ | ​ | ​ | ​ | 3,684 | ​ | ​ | ​ | ​ | ​ | 4,084 | ​ | ​ | ​ | ​ | ​ | 7,159 | ​ | ​ | ​ | ​ | ​ | 6,647 | ​ | ​
Performance Products | ​ | ​ | ​ | ​ | 1,457 | ​ | ​ | ​ | ​ | ​ | 1,514 | ​ | ​ | ​ | ​ | ​ | 2,309 | ​ | ​ | ​ | ​ | ​ | 2,230 | ​ | ​
Total segments | ​ | ​ | ​ | $ | 38,979 | ​ | ​ | ​ | ​ | $ | 41,523 | ​ | ​ | ​ | ​ | $ | 68,367 | ​ | ​ | ​ | ​ | $ | 80,518 | ​ | ​
Reconciliation of income before income taxes to Adjusted EBITDA | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Income before income taxes | ​ | ​ | ​ | $ | 16,895 | ​ | ​ | ​ | ​ | $ | 20,074 | ​ | ​ | ​ | ​ | $ | 20,467 | ​ | ​ | ​ | ​ | $ | 42,779 | ​ | ​
Interest expense, net | ​ | ​ | ​ | ​ | 3,432 | ​ | ​ | ​ | ​ | ​ | 3,015 | ​ | ​ | ​ | ​ | ​ | 6,786 | ​ | ​ | ​ | ​ | ​ | 5,798 | ​ | ​
Depreciation and amortization – Total segments | ​ | ​ | ​ | ​ | 7,757 | ​ | ​ | ​ | ​ | ​ | 6,388 | ​ | ​ | ​ | ​ | ​ | 15,131 | ​ | ​ | ​ | ​ | ​ | 12,614 | ​ | ​
Depreciation and amortization – Corporate | ​ | ​ | ​ | ​ | 391 | ​ | ​ | ​ | ​ | ​ | 453 | ​ | ​ | ​ | ​ | ​ | 798 | ​ | ​ | ​ | ​ | ​ | 918 | ​ | ​
Corporate costs | ​ | ​ | ​ | ​ | 10,491 | ​ | ​ | ​ | ​ | ​ | 9,918 | ​ | ​ | ​ | ​ | ​ | 20,219 | ​ | ​ | ​ | ​ | ​ | 18,804 | ​ | ​
Restructure costs | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 425 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​
Stock-based compensation | ​ | ​ | ​ | ​ | 564 | ​ | ​ | ​ | ​ | ​ | 564 | ​ | ​ | ​ | ​ | ​ | 1,129 | ​ | ​ | ​ | ​ | ​ | 1,129 | ​ | ​
Acquisition-related cost of goods sold | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 280 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​
Acquisition-related transaction costs | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 462 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​
Acquisition-related other | ​ | ​ | ​ | ​ | 167 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 167 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​
Other, net | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (1,506) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (1,506) | ​ | ​
Foreign currency (gains) losses, net | ​ | ​ | ​ | ​ | (718) | ​ | ​ | ​ | ​ | ​ | 2,617 | ​ | ​ | ​ | ​ | ​ | 2,503 | ​ | ​ | ​ | ​ | ​ | (18) | ​ | ​
Adjusted EBITDA – Total segments | ​ | ​ | ​ | $ | 38,979 | ​ | ​ | ​ | ​ | $ | 41,523 | ​ | ​ | ​ | ​ | $ | 68,367 | ​ | ​ | ​ | ​ | $ | 80,518 | ​ | ​
​

As of | ​ | ​ | December 31, 2019 | ​ | ​ | June 30, 2019 | ​
Identifiable assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Animal Health | ​ | ​ | ​ | $ | 572,921 | ​ | ​ | ​ | ​ | $ | 508,864 | ​ | ​
Mineral Nutrition | ​ | ​ | ​ | ​ | 69,988 | ​ | ​ | ​ | ​ | ​ | 67,662 | ​ | ​
Performance Products | ​ | ​ | ​ | ​ | 33,530 | ​ | ​ | ​ | ​ | ​ | 32,886 | ​ | ​
Total segments | ​ | ​ | ​ | ​ | 676,439 | ​ | ​ | ​ | ​ | ​ | 609,412 | ​ | ​
Corporate | ​ | ​ | ​ | ​ | 111,879 | ​ | ​ | ​ | ​ | ​ | 117,259 | ​ | ​
Total | ​ | ​ | ​ | $ | 788,318 | ​ | ​ | ​ | ​ | $ | 726,671 | ​ | ​

The Animal Health segment includes all goodwill of the Company. The Animal Health segment includes advances to and investment in an equity method investee of  $3,548 and $3,287 as of December 31, 2019 and June 30, 2019, respectively. The Performance Products segment includes an investment in an equity method investee of  $852 and $759 as of December 31, 2019 and June 30, 2019, respectively. Corporate assets include cash and cash equivalents, short-term investments, debt issuance costs, income tax related assets and certain other assets.
21

TABLE OF CONTENTS​
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Introduction
Our management’s discussion and analysis of financial condition and results of operations (“MD&A”) is provided to assist readers in understanding our performance, as reflected in the results of our operations, our financial condition and our cash flows. The following discussion summarizes the significant factors affecting our consolidated operating results, financial condition, liquidity and cash flows as of and for the periods presented below. This MD&A should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q. Our future results could differ materially from our historical performance as a result of various factors such as those discussed in “Risk Factors” and “Forward-Looking Statements.”
Overview of our business
Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. We develop, manufacture and market a broad range of products for food animals including poultry, swine, beef and dairy cattle and aquaculture. Our products help prevent, control and treat diseases, enhance nutrition to help improve health and performance and contribute to balanced mineral nutrition. In addition to animal health and mineral nutrition products, we manufacture and market specific ingredients for use in the personal care, industrial chemical and chemical catalyst industries.
22

TABLE OF CONTENTS
Analysis of the consolidated statements of operations
Summary Results of Operations

​ | ​ | ​ | Three Months | ​ | ​ | Six Months | ​
For the Periods Ended December 31 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | Change | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | Change | ​
​ | ​ | ​ | (in thousands, except per share amounts and percentages) | ​
Net sales | ​ | ​ | ​ | $ | 214,012 | ​ | ​ | ​ | ​ | $ | 218,223 | ​ | ​ | ​ | ​ | $ | (4,211) | ​ | ​ | ​ | ​ | ​ | (2)% | ​ | ​ | ​ | ​ | $ | 403,732 | ​ | ​ | ​ | ​ | $ | 418,376 | ​ | ​ | ​ | ​ | $ | (14,644) | ​ | ​ | ​ | ​ | ​ | (4)% | ​ | ​
Gross profit | ​ | ​ | ​ | ​ | 69,104 | ​ | ​ | ​ | ​ | ​ | 68,644 | ​ | ​ | ​ | ​ | ​ | 460 | ​ | ​ | ​ | ​ | ​ | 1% | ​ | ​ | ​ | ​ | ​ | 126,767 | ​ | ​ | ​ | ​ | ​ | 134,449 | ​ | ​ | ​ | ​ | ​ | (7,682) | ​ | ​ | ​ | ​ | ​ | (6)% | ​ | ​
Selling, general and administrative expenses | ​ | ​ | ​ | ​ | 49,495 | ​ | ​ | ​ | ​ | ​ | 42,938 | ​ | ​ | ​ | ​ | ​ | 6,557 | ​ | ​ | ​ | ​ | ​ | 15% | ​ | ​ | ​ | ​ | ​ | 97,011 | ​ | ​ | ​ | ​ | ​ | 85,890 | ​ | ​ | ​ | ​ | ​ | 11,121 | ​ | ​ | ​ | ​ | ​ | 13% | ​ | ​
Operating income | ​ | ​ | ​ | ​ | 19,609 | ​ | ​ | ​ | ​ | ​ | 25,706 | ​ | ​ | ​ | ​ | ​ | (6,097) | ​ | ​ | ​ | ​ | ​ | (24)% | ​ | ​ | ​ | ​ | ​ | 29,756 | ​ | ​ | ​ | ​ | ​ | 48,559 | ​ | ​ | ​ | ​ | ​ | (18,803) | ​ | ​ | ​ | ​ | ​ | (39)% | ​ | ​
Interest expense, net | ​ | ​ | ​ | ​ | 3,432 | ​ | ​ | ​ | ​ | ​ | 3,015 | ​ | ​ | ​ | ​ | ​ | 417 | ​ | ​ | ​ | ​ | ​ | 14% | ​ | ​ | ​ | ​ | ​ | 6,786 | ​ | ​ | ​ | ​ | ​ | 5,798 | ​ | ​ | ​ | ​ | ​ | 988 | ​ | ​ | ​ | ​ | ​ | 17% | ​ | ​
Foreign currency (gains) losses, net | ​ | ​ | ​ | ​ | (718) | ​ | ​ | ​ | ​ | ​ | 2,617 | ​ | ​ | ​ | ​ | ​ | (3,335) | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ | ​ | ​ | ​ | 2,503 | ​ | ​ | ​ | ​ | ​ | (18) | ​ | ​ | ​ | ​ | ​ | 2,521 | ​ | ​ | ​ | ​ | ​ | * | ​ | ​
Income before income taxes | ​ | ​ | ​ | ​ | 16,895 | ​ | ​ | ​ | ​ | ​ | 20,074 | ​ | ​ | ​ | ​ | ​ | (3,179) | ​ | ​ | ​ | ​ | ​ | (16)% | ​ | ​ | ​ | ​ | ​ | 20,467 | ​ | ​ | ​ | ​ | ​ | 42,779 | ​ | ​ | ​ | ​ | ​ | (22,312) | ​ | ​ | ​ | ​ | ​ | (52)% | ​ | ​
Provision for income taxes | ​ | ​ | ​ | ​ | 5,001 | ​ | ​ | ​ | ​ | ​ | 5,326 | ​ | ​ | ​ | ​ | ​ | (325) | ​ | ​ | ​ | ​ | ​ | (6)% | ​ | ​ | ​ | ​ | ​ | 6,058 | ​ | ​ | ​ | ​ | ​ | 11,717 | ​ | ​ | ​ | ​ | ​ | (5,659) | ​ | ​ | ​ | ​ | ​ | (48)% | ​ | ​
Net income | ​ | ​ | ​ | $ | 11,894 | ​ | ​ | ​ | ​ | $ | 14,748 | ​ | ​ | ​ | ​ | $ | (2,854) | ​ | ​ | ​ | ​ | ​ | (19)% | ​ | ​ | ​ | ​ | $ | 14,409 | ​ | ​ | ​ | ​ | $ | 31,062 | ​ | ​ | ​ | ​ | $ | (16,653) | ​ | ​ | ​ | ​ | ​ | (54)% | ​ | ​
Net income per share | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
basic | ​ | ​ | ​ | $ | 0.29 | ​ | ​ | ​ | ​ | $ | 0.37 | ​ | ​ | ​ | ​ | $ | (0.08) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 0.36 | ​ | ​ | ​ | ​ | $ | 0.77 | ​ | ​ | ​ | ​ | $ | (0.41) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
diluted | ​ | ​ | ​ | $ | 0.29 | ​ | ​ | ​ | ​ | $ | 0.36 | ​ | ​ | ​ | ​ | $ | (0.07) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 0.36 | ​ | ​ | ​ | ​ | $ | 0.77 | ​ | ​ | ​ | ​ | $ | (0.41) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted average number of shares outstanding | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
basic | ​ | ​ | ​ | ​ | 40,454 | ​ | ​ | ​ | ​ | ​ | 40,383 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 40,454 | ​ | ​ | ​ | ​ | ​ | 40,376 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
diluted | ​ | ​ | ​ | ​ | 40,504 | ​ | ​ | ​ | ​ | ​ | 40,523 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 40,504 | ​ | ​ | ​ | ​ | ​ | 40,523 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Ratio to net sales | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gross profit | ​ | ​ | ​ | ​ | 32.3% | ​ | ​ | ​ | ​ | ​ | 31.5% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 31.4% | ​ | ​ | ​ | ​ | ​ | 32.1% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Selling, general and administrative expenses | ​ | ​ | ​ | ​ | 23.1% | ​ | ​ | ​ | ​ | ​ | 19.7% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 24.0% | ​ | ​ | ​ | ​ | ​ | 20.5% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income | ​ | ​ | ​ | ​ | 9.2% | ​ | ​ | ​ | ​ | ​ | 11.8% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 7.4% | ​ | ​ | ​ | ​ | ​ | 11.6% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Income before income taxes | ​ | ​ | ​ | ​ | 7.9% | ​ | ​ | ​ | ​ | ​ | 9.2% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 5.1% | ​ | ​ | ​ | ​ | ​ | 10.2% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income | ​ | ​ | ​ | ​ | 5.6% | ​ | ​ | ​ | ​ | ​ | 6.8% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 3.6% | ​ | ​ | ​ | ​ | ​ | 7.4% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Effective tax rate | ​ | ​ | ​ | ​ | 29.6% | ​ | ​ | ​ | ​ | ​ | 26.5% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 29.6% | ​ | ​ | ​ | ​ | ​ | 27.4% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

​
Certain amounts and percentages may reflect rounding adjustments.
*
Calculation not meaningful
​
​
23

TABLE OF CONTENTS
Net sales, Adjusted EBITDA and reconciliation of GAAP net income to Adjusted EBITDA
We report Net sales and Adjusted EBITDA by segment to understand the operating performance of each segment. This enables us to monitor changes in net sales, costs and other actionable operating metrics at the segment level. See “—General description of non-GAAP financial measures.”
Segment net sales and Adjusted EBITDA:

​ | ​ | ​ | Three Months | ​ | ​ | Six Months | ​
For the Periods Ended December 31 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | Change | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | Change | ​
​ | ​ | ​ | (in thousands, except percentages) | ​
Net sales | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
MFAs and other | ​ | ​ | ​ | $ | 91,955 | ​ | ​ | ​ | ​ | $ | 93,054 | ​ | ​ | ​ | ​ | $ | (1,099) | ​ | ​ | ​ | ​ | ​ | (1)% | ​ | ​ | ​ | ​ | $ | 166,989 | ​ | ​ | ​ | ​ | $ | 180,058 | ​ | ​ | ​ | ​ | $ | (13,069) | ​ | ​ | ​ | ​ | ​ | (7)% | ​ | ​
Nutritional specialties | ​ | ​ | ​ | ​ | 33,062 | ​ | ​ | ​ | ​ | ​ | 29,460 | ​ | ​ | ​ | ​ | ​ | 3,602 | ​ | ​ | ​ | ​ | ​ | 12% | ​ | ​ | ​ | ​ | ​ | 63,495 | ​ | ​ | ​ | ​ | ​ | 56,430 | ​ | ​ | ​ | ​ | ​ | 7,065 | ​ | ​ | ​ | ​ | ​ | 13% | ​ | ​
Vaccines | ​ | ​ | ​ | ​ | 18,672 | ​ | ​ | ​ | ​ | ​ | 17,048 | ​ | ​ | ​ | ​ | ​ | 1,624 | ​ | ​ | ​ | ​ | ​ | 10% | ​ | ​ | ​ | ​ | ​ | 35,055 | ​ | ​ | ​ | ​ | ​ | 34,263 | ​ | ​ | ​ | ​ | ​ | 792 | ​ | ​ | ​ | ​ | ​ | 2% | ​ | ​
Animal Health | ​ | ​ | ​ | ​ | 143,689 | ​ | ​ | ​ | ​ | ​ | 139,562 | ​ | ​ | ​ | ​ | ​ | 4,127 | ​ | ​ | ​ | ​ | ​ | 3% | ​ | ​ | ​ | ​ | ​ | 265,539 | ​ | ​ | ​ | ​ | ​ | 270,751 | ​ | ​ | ​ | ​ | ​ | (5,212) | ​ | ​ | ​ | ​ | ​ | (2)% | ​ | ​
Mineral Nutrition | ​ | ​ | ​ | ​ | 55,685 | ​ | ​ | ​ | ​ | ​ | 62,319 | ​ | ​ | ​ | ​ | ​ | (6,634) | ​ | ​ | ​ | ​ | ​ | (11)% | ​ | ​ | ​ | ​ | ​ | 108,334 | ​ | ​ | ​ | ​ | ​ | 117,157 | ​ | ​ | ​ | ​ | ​ | (8,823) | ​ | ​ | ​ | ​ | ​ | (8)% | ​ | ​
Performance Products | ​ | ​ | ​ | ​ | 14,638 | ​ | ​ | ​ | ​ | ​ | 16,342 | ​ | ​ | ​ | ​ | ​ | (1,704) | ​ | ​ | ​ | ​ | ​ | (10)% | ​ | ​ | ​ | ​ | ​ | 29,859 | ​ | ​ | ​ | ​ | ​ | 30,468 | ​ | ​ | ​ | ​ | ​ | (609) | ​ | ​ | ​ | ​ | ​ | (2)% | ​ | ​
Total | ​ | ​ | ​ | $ | 214,012 | ​ | ​ | ​ | ​ | $ | 218,223 | ​ | ​ | ​ | ​ | $ | (4,211) | ​ | ​ | ​ | ​ | ​ | (2)% | ​ | ​ | ​ | ​ | $ | 403,732 | ​ | ​ | ​ | ​ | $ | 418,376 | ​ | ​ | ​ | ​ | $ | (14,644) | ​ | ​ | ​ | ​ | ​ | (4)% | ​ | ​
Adjusted EBITDA | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Animal Health | ​ | ​ | ​ | $ | 33,838 | ​ | ​ | ​ | ​ | $ | 35,925 | ​ | ​ | ​ | ​ | $ | (2,087) | ​ | ​ | ​ | ​ | ​ | (6)% | ​ | ​ | ​ | ​ | $ | 58,899 | ​ | ​ | ​ | ​ | $ | 71,641 | ​ | ​ | ​ | ​ | $ | (12,742) | ​ | ​ | ​ | ​ | ​ | (18)% | ​ | ​
Mineral Nutrition | ​ | ​ | ​ | ​ | 3,684 | ​ | ​ | ​ | ​ | ​ | 4,084 | ​ | ​ | ​ | ​ | ​ | (400) | ​ | ​ | ​ | ​ | ​ | (10)% | ​ | ​ | ​ | ​ | ​ | 7,159 | ​ | ​ | ​ | ​ | ​ | 6,647 | ​ | ​ | ​ | ​ | ​ | 512 | ​ | ​ | ​ | ​ | ​ | 8% | ​ | ​
Performance Products | ​ | ​ | ​ | ​ | 1,457 | ​ | ​ | ​ | ​ | ​ | 1,514 | ​ | ​ | ​ | ​ | ​ | (57) | ​ | ​ | ​ | ​ | ​ | (4)% | ​ | ​ | ​ | ​ | ​ | 2,309 | ​ | ​ | ​ | ​ | ​ | 2,230 | ​ | ​ | ​ | ​ | ​ | 79 | ​ | ​ | ​ | ​ | ​ | 4% | ​ | ​
Corporate | ​ | ​ | ​ | ​ | (10,491) | ​ | ​ | ​ | ​ | ​ | (9,918) | ​ | ​ | ​ | ​ | ​ | (573) | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ | ​ | ​ | ​ | (20,219) | ​ | ​ | ​ | ​ | ​ | (18,804) | ​ | ​ | ​ | ​ | ​ | (1,415) | ​ | ​ | ​ | ​ | ​ | * | ​ | ​
Total | ​ | ​ | ​ | $ | 28,488 | ​ | ​ | ​ | ​ | $ | 31,605 | ​ | ​ | ​ | ​ | $ | (3,117) | ​ | ​ | ​ | ​ | ​ | (10)% | ​ | ​ | ​ | ​ | $ | 48,148 | ​ | ​ | ​ | ​ | $ | 61,714 | ​ | ​ | ​ | ​ | $ | (13,566) | ​ | ​ | ​ | ​ | ​ | (22)% | ​ | ​
Adjusted EBITDA ratio to segment net sales | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Animal Health | ​ | ​ | ​ | ​ | 23.5% | ​ | ​ | ​ | ​ | ​ | 25.7% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 22.2% | ​ | ​ | ​ | ​ | ​ | 26.5% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Mineral Nutrition | ​ | ​ | ​ | ​ | 6.6% | ​ | ​ | ​ | ​ | ​ | 6.6% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 6.6% | ​ | ​ | ​ | ​ | ​ | 5.7% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Performance Products | ​ | ​ | ​ | ​ | 10.0% | ​ | ​ | ​ | ​ | ​ | 9.3% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 7.7% | ​ | ​ | ​ | ​ | ​ | 7.3% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Corporate(1) | ​ | ​ | ​ | ​ | (4.9)% | ​ | ​ | ​ | ​ | ​ | (4.5)% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (5.0)% | ​ | ​ | ​ | ​ | ​ | (4.5)% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total(1) | ​ | ​ | ​ | ​ | 13.3% | ​ | ​ | ​ | ​ | ​ | 14.5% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 11.9% | ​ | ​ | ​ | ​ | ​ | 14.8% | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

​
(1)
reflects ratio to total net sales
​
​
24

TABLE OF CONTENTS
The table below sets forth a reconciliation of net income, as reported under GAAP, to Adjusted EBITDA:

​ | ​ | ​ | Three Months | ​ | ​ | Six Months | ​
For the Periods Ended December 31 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | Change | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | Change | ​
​ | ​ | ​ | (in thousands, except percentages) | ​
Net income | ​ | ​ | ​ | $ | 11,894 | ​ | ​ | ​ | ​ | $ | 14,748 | ​ | ​ | ​ | ​ | $ | (2,854) | ​ | ​ | ​ | ​ | ​ | (19)% | ​ | ​ | ​ | ​ | $ | 14,409 | ​ | ​ | ​ | ​ | $ | 31,062 | ​ | ​ | ​ | ​ | $ | (16,653) | ​ | ​ | ​ | ​ | ​ | (54)% | ​ | ​
Interest expense, net | ​ | ​ | ​ | ​ | 3,432 | ​ | ​ | ​ | ​ | ​ | 3,015 | ​ | ​ | ​ | ​ | ​ | 417 | ​ | ​ | ​ | ​ | ​ | 14% | ​ | ​ | ​ | ​ | ​ | 6,786 | ​ | ​ | ​ | ​ | ​ | 5,798 | ​ | ​ | ​ | ​ | ​ | 988 | ​ | ​ | ​ | ​ | ​ | 17% | ​ | ​
Provision for income taxes | ​ | ​ | ​ | ​ | 5,001 | ​ | ​ | ​ | ​ | ​ | 5,326 | ​ | ​ | ​ | ​ | ​ | (325) | ​ | ​ | ​ | ​ | ​ | (6)% | ​ | ​ | ​ | ​ | ​ | 6,058 | ​ | ​ | ​ | ​ | ​ | 11,717 | ​ | ​ | ​ | ​ | ​ | (5,659) | ​ | ​ | ​ | ​ | ​ | (48)% | ​ | ​
Depreciation and amortization | ​ | ​ | ​ | ​ | 8,148 | ​ | ​ | ​ | ​ | ​ | 6,841 | ​ | ​ | ​ | ​ | ​ | 1,307 | ​ | ​ | ​ | ​ | ​ | 19% | ​ | ​ | ​ | ​ | ​ | 15,929 | ​ | ​ | ​ | ​ | ​ | 13,532 | ​ | ​ | ​ | ​ | ​ | 2,397 | ​ | ​ | ​ | ​ | ​ | 18% | ​ | ​
EBITDA | ​ | ​ | ​ | ​ | 28,475 | ​ | ​ | ​ | ​ | ​ | 29,930 | ​ | ​ | ​ | ​ | ​ | (1,455) | ​ | ​ | ​ | ​ | ​ | (5)% | ​ | ​ | ​ | ​ | ​ | 43,182 | ​ | ​ | ​ | ​ | ​ | 62,109 | ​ | ​ | ​ | ​ | ​ | (18,927) | ​ | ​ | ​ | ​ | ​ | (30)% | ​ | ​
Restructuring costs | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ | ​ | ​ | ​ | 425 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 425 | ​ | ​ | ​ | ​ | ​ | * | ​ | ​
Stock-based compensation | ​ | ​ | ​ | ​ | 564 | ​ | ​ | ​ | ​ | ​ | 564 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 0% | ​ | ​ | ​ | ​ | ​ | 1,129 | ​ | ​ | ​ | ​ | ​ | 1,129 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 0% | ​ | ​
Acquisition-related cost of goods sold | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ | ​ | ​ | ​ | 280 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 280 | ​ | ​ | ​ | ​ | ​ | * | ​ | ​
Acquisition-related transaction costs | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ | ​ | ​ | ​ | 462 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 462 | ​ | ​ | ​ | ​ | ​ | * | ​ | ​
Acquisition-related other, net | ​ | ​ | ​ | ​ | 167 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 167 | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ | ​ | ​ | ​ | 167 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 167 | ​ | ​ | ​ | ​ | ​ | * | ​ | ​
Other, net | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (1,506) | ​ | ​ | ​ | ​ | ​ | 1,506 | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (1,506) | ​ | ​ | ​ | ​ | ​ | 1,506 | ​ | ​ | ​ | ​ | ​ | * | ​ | ​
Foreign currency (gains) losses, net | ​ | ​ | ​ | ​ | (718) | ​ | ​ | ​ | ​ | ​ | 2,617 | ​ | ​ | ​ | ​ | ​ | (3,335) | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ | ​ | ​ | ​ | 2,503 | ​ | ​ | ​ | ​ | ​ | (18) | ​ | ​ | ​ | ​ | ​ | 2,521 | ​ | ​ | ​ | ​ | ​ | * | ​ | ​
Adjusted EBITDA | ​ | ​ | ​ | $ | 28,488 | ​ | ​ | ​ | ​ | $ | 31,605 | ​ | ​ | ​ | ​ | $ | (3,117) | ​ | ​ | ​ | ​ | ​ | (10)% | ​ | ​ | ​ | ​ | $ | 48,148 | ​ | ​ | ​ | ​ | $ | 61,714 | ​ | ​ | ​ | ​ | $ | (13,566) | ​ | ​ | ​ | ​ | ​ | (22)% | ​ | ​
​

​
Certain amounts and percentages may reflect rounding adjustments.
*
Calculation not meaningful
​
Comparison of three months ended December 31, 2019 and 2018
Net sales
Net sales of  $214.0 million for the three months ended December 31, 2019, decreased $4.2 million, or 2%, as compared to the three months ended December 31, 2018. Animal Health increased $4.1 million, while Mineral Nutrition and Performance Products declined $6.6 million and $1.7 million, respectively.
Animal Health
Net sales of  $143.7 million for the three months ended December 31, 2019, increased $4.1 million, or 3%. Net sales of MFAs and other declined $1.1 million, or 1%. Increased domestic sales were offset by reduced sales in China due to the effects of African Swine Fever. China customers purchased MFAs in advance of regulatory changes that were effective January 1, 2020. Net sales of nutritional specialty products grew $3.6 million, or 12%. The recent Osprey acquisition accounted for approximately two-thirds of the nutritional specialties sales growth. We experienced growth in net sales of domestic poultry and dairy products, partially offset by lower international sales. The increase in the domestic poultry segment was driven by the introduction of Provia Prime™, a direct fed microbial product that helps optimize the gut microbiome for improved health, immunity and productivity. Net sales of vaccines increased $1.6 million, or 10%, driven by strong international demand and increased market penetration.
Mineral Nutrition
Net sales of  $55.7 million for the three months ended December 31, 2019, decreased $6.6 million, or 11%, due to lower average selling prices coupled with lower overall unit volume. The decline in average selling prices is correlated with the movement of the underlying raw material costs.
Performance Products
Net sales of  $14.6 million for the three months ended December 31, 2019, decreased $1.7 million, or 10%, driven by lower volume of copper-based products, partially offset by increased volumes of personal care products.
25

TABLE OF CONTENTS
Gross profit
Gross profit of  $69.1 million for the three months ended December 31, 2019, increased $0.5 million, or 1%, as compared to the three months ended December 31, 2018. Gross profit increased to 32.3% of net sales for the three months ended December 31, 2019, as compared to 31.5% for the three months ended December 31, 2018.
Animal Health gross profit increased $1.1 million due to volume growth in nutritional specialty and vaccine products, partially offset by lower volume in MFAs and other. Mineral Nutrition gross profit decreased $0.5 million, as the decline in average selling prices and unfavorable product mix more than offset lower raw material costs. Performance Products gross profit decreased $0.1 million due to decreased volume, partially offset by favorable product mix.
Selling, general and administrative expenses
Selling, general and administrative expenses (“SG&A”) of  $49.5 million for the three months ended December 31, 2019, increased $6.6 million, or 15%, as compared to the three months ended December 31, 2018. SG&A for the three months ended December 31, 2019, included $0.6 million of stock-based compensation and $0.2 million of other acquisition-related costs. SG&A for the three months ended December 31, 2018, included $0.6 million of stock-based compensation and a $1.5 million benefit from the cancellation of a certain business arrangement. Excluding the effects of these costs, SG&A increased $4.9 million, or 11%.
Animal Health SG&A increased $4.4 million, including increased investments in product development and the effect of the Osprey acquisition. Mineral Nutrition and Performance Products SG&A were comparable to the prior year. Corporate expenses increased $0.5 million due to increased costs of strategic initiatives and public company costs. Stock-based compensation, other acquisition-related costs and the benefit in the prior year from the cancellation of a certain business arrangement resulted in a net $1.7 million increase to SG&A.
Interest expense, net
Interest expense, net of  $3.4 million for the three months ended December 31, 2019, increased $0.4 million, or 14%, as compared to the three months ended December 31, 2018. The increase in interest expense was primarily driven by the increase in outstanding borrowings on the Revolver. Interest income from short-term investments was comparable to the prior year.
Foreign currency (gains) losses, net
Foreign currency (gains) losses, net for the three months ended December 31, 2019, amounted to net gains of  $0.7 million, as compared to $2.6 million in net losses for the three months ended December 31, 2018. Foreign currency gains and losses primarily arose from intercompany balances.
Provision for income taxes
The provision for income taxes was $5.0 million and $5.3 million for the three months ended December 31, 2019 and 2018, respectively. The effective income tax rate was 29.6% and 26.5% for the three months ended December 31, 2019 and 2018, respectively. The provision for income taxes during the three months ended December 31, 2018, included a $0.7 million benefit from an adjustment to the previously recorded mandatory toll charge on deemed repatriation of undistributed earnings of foreign subsidiaries and a $0.1 million benefit from the exercise of employee stock options. The effective income tax rate, without these benefits, would have been 30.5% for the three months ended December 31, 2018.
Net income
Net income of  $11.9 million for the three months ended December 31, 2019, decreased $2.9 million, as compared to net income of $14.8 million for the three months ended December 31, 2018. The decrease was primarily due to a $6.1 million decline in operating income and increased interest expense of  $0.4 million, partially offset by favorable foreign currency movements of  $3.3 million and lower income
26

TABLE OF CONTENTS
tax expense of   $0.3 million. The decline in operating income was driven by increased SG&A costs of $6.6 million as a result of investments in product development and the effect of the Osprey acquisition, partially offset by $0.5 million of increased gross profit.
Adjusted EBITDA
Adjusted EBITDA of  $28.5 million for the three months ended December 31, 2019, decreased $3.1 million, or 10%, as compared to the three months ended December 31, 2018. Animal Health Adjusted EBITDA decreased $2.1 million due to increased SG&A costs as a result of investments in product development and the effect of the Osprey acquisition, partially offset by increased gross profit driven by volume growth. Mineral Nutrition Adjusted EBITDA decreased $0.4 million, driven by decreased gross profit. Performance Products Adjusted EBITDA was comparable to the prior year. Corporate expenses increased $0.6 million due to increased professional service and public company costs.
Comparison of six months ended December 31, 2019 and 2018
Net sales
Net sales of  $403.7 million for the six months ended December 31, 2019, decreased $14.6 million, or 4%, as compared to the six months ended December 31, 2018. Animal Health, Mineral Nutrition and Performance Products declined $5.2 million, $8.8 million and $0.6 million, respectively.
Animal Health
Net sales of  $265.5 million for the six months ended December 31, 2019, declined $5.2 million, or 2%. Net sales of MFAs and other declined $13.1 million, or 7%, due to reduced demand related to the effect of African Swine Fever in China. Net sales growth in other products and regions were a partial offset. Net sales of nutritional specialty products grew $7.1 million, or 13%, due to volume growth in poultry and dairy products. The recent Osprey acquisition accounted for approximately two-thirds of the nutritional specialty sales growth. Net sales of vaccines increased $0.8 million, or 2%, due to international demand and increased market penetration. Net sales of vaccines would have increased approximately 7%, excluding the loss of a domestic distribution arrangement in October 2018.
Mineral Nutrition
Net sales of  $108.3 million for the six months ended December 31, 2019, decreased $8.8 million, or 8%, driven by lower average selling prices and decreased unit volumes. The decline in average selling prices is correlated with the movement of the underlying raw material costs.
Performance Products
Net sales of  $29.9 million for the six months ended December 31, 2019, decreased $0.6 million, or 2%. Increased volumes of personal care ingredients were more than offset by lower volume of copper-based products.
Gross profit
Gross profit of  $126.8 million for the six months ended December 31, 2019, decreased $7.7 million, or 6%, as compared to the six months ended December 31, 2018. Gross profit decreased to 31.4% of net sales for the six months ended December 31, 2019, as compared to 32.1% for the six months ended December 31, 2018. The six months ended December 31, 2019, included $0.3 million of acquisition-related cost of goods sold.
Animal Health gross profit decreased $7.5 million due to volume declines and unfavorable product mix in MFAs and other, partially offset by volume growth in nutritional specialty products. Gross profit from vaccine products was comparable to the prior year. Mineral Nutrition gross profit increased $0.4 million, as favorable raw material costs and product mix offset the decline in average selling prices. Performance Products gross profit decreased $0.3 million due to unfavorable manufacturing costs.
27

TABLE OF CONTENTS
Selling, general and administrative expenses
Selling, general and administrative expenses (“SG&A”) of  $97.0 million for the six months ended December 31, 2019, increased $11.1 million, or 13%, as compared to the six months ended December 31, 2018. SG&A for the six months ended December 31, 2019, included $0.4 million of restructuring costs, $1.1 million of stock-based compensation, 0.5 million of acquisition-related transaction costs and $0.2 million of other acquisition-related costs. SG&A for the six months ended December 31, 2018, included $1.1 million of stock-based compensation and a $1.5 million benefit from the cancellation of a certain business arrangement. Excluding the effects of these costs, SG&A increased $8.5 million, or 10%.
Animal Health SG&A increased $7.5 million, including increased investments in product development and the effect of the Osprey acquisition. Mineral Nutrition and Performance Products SG&A decreased $0.1 million and $0.2 million, respectively. Corporate expenses increased $1.3 million due to increased costs of strategic initiatives and public company costs. The restructuring costs, stock-based compensation, acquisition-related transaction costs, other acquisition-related costs and the benefit in the prior year from the cancellation of a certain business arrangement resulted in a net $2.6 million increase to SG&A.
Interest expense, net
Interest expense, net of  $6.8 million for the six months ended December 31, 2019, increased $1.0 million, or 17%, as compared to the six months ended December 31, 2018. The increase in interest expense was primarily driven by the increase in outstanding borrowings on the Revolver. Interest income from short-term investments was comparable to the prior year.
Foreign currency (gains) losses, net
Foreign currency (gains) losses, net for the six months ended December 31, 2019, amounted to net losses of $2.5 million, as compared to a nominal amount for the six months ended December 31, 2018. Foreign currency gains and losses primarily arose from intercompany balances and the effects of currency devaluations in both Argentina and Turkey.
Provision for income taxes
The provision for income taxes was $6.1 million and $11.7 million for the six months ended December 31, 2019 and 2018, respectively. The effective income tax rate was 29.6% and 27.4% for the six months ended December 31, 2019 and 2018, respectively. The provision for income taxes during the six months ended December 31, 2018 included a $0.7 million benefit from an adjustment to the previously recorded mandatory toll charge on deemed repatriation of undistributed earnings of foreign subsidiaries and a $0.2 million benefit from the exercise of employee stock options. The effective income tax rate, without these benefits, would have been 29.6% for the six months ended December 31, 2018.
Net income
Net income of $14.4 million for the six months ended December 31, 2019, decreased $16.7 million, as compared to net income of $31.1 million for the six months ended December 31, 2018. The decrease was primarily due to an $18.8 million decline in operating income coupled with unfavorable foreign currency movements of  $2.5 million and increased interest expense of  $1.0 million, partially offset by lower income tax expense of  $5.6 million. The decline in operating income was driven by a $7.7 million reduction in gross profit, on reduced volumes and unfavorable product mix, and increased SG&A costs of  $11.1 million as we continue to invest in product development and strategic growth initiatives.
Adjusted EBITDA
Adjusted EBITDA of  $48.1 million for the six months ended December 31, 2019, decreased $13.6 million, or 22%, as compared to the six months ended December 31, 2018. Animal Health Adjusted EBITDA decreased $12.7 million due to reduced sales volumes and the related gross profit decline, coupled with increased SG&A costs for product development and strategic growth initiatives. Mineral Nutrition
28

TABLE OF CONTENTS
Adjusted EBITDA increased $0.5 million, driven by increased gross profit. Performance Products Adjusted EBITDA was comparable to the prior year. Corporate expenses increased $1.4 million due to increased costs of strategic initiatives and public company costs.
Analysis of financial condition, liquidity and capital resources
Net increase (decrease) in cash and cash equivalents was:

​ | ​ | ​ | Six Months | ​
For the Periods Ended December 31 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | Change | ​
​ | ​ | ​ | (in thousands) | ​
Cash provided by/(used in): | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating activities | ​ | ​ | ​ | $ | 28,521 | ​ | ​ | ​ | ​ | $ | 16,636 | ​ | ​ | ​ | ​ | $ | 11,737 | ​ | ​
Investing activities | ​ | ​ | ​ | ​ | (96,709) | ​ | ​ | ​ | ​ | ​ | (20,928) | ​ | ​ | ​ | ​ | ​ | (75,633) | ​ | ​
Financing activities | ​ | ​ | ​ | ​ | 36,930 | ​ | ​ | ​ | ​ | ​ | 6,874 | ​ | ​ | ​ | ​ | ​ | 30,056 | ​ | ​
Effect of exchange-rate changes on cash and cash equivalents | ​ | ​ | ​ | ​ | (135) | ​ | ​ | ​ | ​ | ​ | (414) | ​ | ​ | ​ | ​ | ​ | 279 | ​ | ​
Net increase/(decrease) in cash and cash equivalents | ​ | ​ | ​ | $ | (31,393) | ​ | ​ | ​ | ​ | $ | 2,168 | ​ | ​ | ​ | ​ | $ | (33,561) | ​ | ​

​
Certain amounts may reflect rounding adjustments.
Net cash provided (used) by operating activities was comprised of:

​ | ​ | ​ | Six Months | ​
For the Periods Ended December 31 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​ | Change | ​
​ | ​ | ​ | (in thousands) | ​
EBITDA | ​ | ​ | ​ | $ | 43,182 | ​ | ​ | ​ | ​ | $ | 62,109 | ​ | ​ | ​ | ​ | $ | (18,927) | ​ | ​
Adjustments | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Restructuring costs | ​ | ​ | ​ | ​ | 425 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 425 | ​ | ​
Stock-based compensation | ​ | ​ | ​ | ​ | 1,129 | ​ | ​ | ​ | ​ | ​ | 1,129 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​
Acquisition-related cost of goods sold | ​ | ​ | ​ | ​ | 280 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 280 | ​ | ​
Acquisition-related transaction costs | ​ | ​ | ​ | ​ | 462 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 462 | ​ | ​
Acquisition other, net | ​ | ​ | ​ | ​ | 167 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 167 | ​ | ​
Other, net | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (1,506) | ​ | ​ | ​ | ​ | ​ | 1,506 | ​ | ​
Foreign currency (gains) losses, net | ​ | ​ | ​ | ​ | 2,503 | ​ | ​ | ​ | ​ | ​ | (18) | ​ | ​ | ​ | ​ | ​ | 2,521 | ​ | ​
Interest paid | ​ | ​ | ​ | ​ | (6,261) | ​ | ​ | ​ | ​ | ​ | (5,874) | ​ | ​ | ​ | ​ | ​ | (387) | ​ | ​
Income taxes paid | ​ | ​ | ​ | ​ | (9,357) | ​ | ​ | ​ | ​ | ​ | (10,490) | ​ | ​ | ​ | ​ | ​ | 1,133 | ​ | ​
Changes in operating assets and liabilities and other items | ​ | ​ | ​ | ​ | (3,547) | ​ | ​ | ​ | ​ | ​ | (28,714) | ​ | ​ | ​ | ​ | ​ | 25,019 | ​ | ​
Cash used for acquisition-related transaction costs | ​ | ​ | ​ | ​ | (462) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (462) | ​ | ​
Net cash provided (used) by operating activities | ​ | ​ | ​ | $ | 28,521 | ​ | ​ | ​ | ​ | $ | 16,636 | ​ | ​ | ​ | ​ | $ | 11,737 | ​ | ​

​
Certain amounts may reflect rounding adjustments.
Operating activities
Net cash provided by operating activities was $28.5 million for the six months ended December 31, 2019. Cash provided by net income and non-cash items of $32.0 million, including depreciation and amortization, was offset by $3.5 million of cash used in the ordinary course of business for changes in operating assets and liabilities and other items. Cash uses included $14.1 million for accounts payable and $2.3 million for prepaid expenses and other due to the timing of payments for inventory purchases. Cash was provided by accounts receivable of  $12.9 million due to the timing of sales and collections in international regions.
29

TABLE OF CONTENTS
Investing activities
Net cash used in investing activities was $96.7 million for the six months ended December 31, 2019. Cash used for the Osprey acquisition was $54.5 million. We invested $25.0 million in short-term investments. Capital expenditures were $16.1 million as we continued to invest in our existing asset base and for capacity expansion and productivity improvements.
Financing activities
Net cash provided by financing activities was $36.9 million for the six months ended December 31, 2019. Net borrowings on our Revolver provided $53.0 million, primarily to fund the cash paid for the Osprey acquisition. We paid $9.7 million in dividends to holders of our Class A and Class B common stock. We paid $6.4 million in scheduled debt and other requirements.
Liquidity and capital resources
We believe our cash on hand, our operating cash flows and our financing arrangements, including the availability of borrowings under the Revolver and foreign credit lines, will be sufficient to support our ongoing cash needs. Our operating plan projects adequate liquidity throughout the year. However, we can provide no assurance that our liquidity and capital resources will be adequate for future funding requirements. We believe we will be able to comply with the terms of the covenants under the Credit Facilities and foreign credit lines based on our operating plan. In the event of adverse operating results and/or violation of covenants under the facilities, there can be no assurance we would be able to obtain waivers or amendments. Other risks to our meeting future funding requirements include global economic conditions and macroeconomic, business and financial disruptions that could arise. There can be no assurance that a challenging economic environment or an economic downturn would not affect our liquidity or our ability to obtain future financing. In addition, our debt covenants may restrict our ability to invest.
Certain relevant measures of our liquidity and capital resources follow:

As of | ​ | ​ | December 31, 2019 | ​ | ​ | June 30, 2019 | ​
​ | ​ | ​ | (in thousands, except ratios) | ​
Cash and cash equivalents and short-term investments | ​ | ​ | ​ | $ | 75,180 | ​ | ​ | ​ | ​ | $ | 81,573 | ​ | ​
Working capital | ​ | ​ | ​ | ​ | 238,873 | ​ | ​ | ​ | ​ | ​ | 242,902 | ​ | ​
Ratio of current assets to current liabilities | ​ | ​ | ​ | ​ | 2.82:1 | ​ | ​ | ​ | ​ | ​ | 2.71:1 | ​ | ​

We define working capital as total current assets (excluding cash and cash equivalents and short-term investments) less total current liabilities (excluding current portion of long-term debt). We calculate the ratio of current assets to current liabilities based on this definition.
At December 31, 2019, we had $149.0 million in outstanding borrowings under the Revolver. We had outstanding letters of credit and other commitments of   $2.7 million, leaving $98.3 million available for borrowings and letters of credit.
We currently intend to pay quarterly dividends on our Class A and Class B common stock, subject to approval from the Board of Directors. On February 3, 2020, our Board of Directors declared a cash dividend of   $0.12 per share on Class A and Class B common stock outstanding on the record date of March 4, 2020, payable on March 25, 2020. Our future ability to pay dividends will depend upon our results of operations, financial condition, capital requirements, our ability to obtain funds from our subsidiaries and other factors that our Board of Directors deems relevant. Additionally, the terms of our current and any future agreements governing our indebtedness could limit our ability to pay dividends or make other distributions.
As of December 31, 2019, our cash and cash equivalents and short-term investments included $73.2 million held by our international subsidiaries. There are no restrictions on cash distributions to PAHC from our international subsidiaries.
30

TABLE OF CONTENTS
Contractual obligations
As of December 31, 2019, there were no material changes in payments due under contractual obligations from those disclosed in the Annual Report on Form 10-K for the year ended June 30, 2019.
Off-balance sheet arrangements
We do not currently use off-balance sheet arrangements for the purpose of credit enhancement, hedging transactions, investment or other financial purposes.
In the ordinary course of business, we may indemnify our counterparties against certain liabilities that may arise. These indemnifications typically pertain to environmental matters. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications generally are subject to certain restrictions and limitations.
Adjusted EBITDA
Adjusted EBITDA is an alternative view of performance used by management as our primary operating measure, and we believe that investors’ understanding of our performance is enhanced by disclosing this performance measure. We report Adjusted EBITDA to portray the results of our operations prior to considering certain income statement elements. We have defined EBITDA as net income (loss) plus (i) interest expense, net, (ii) provision for income taxes or less benefit for income taxes, and (iii) depreciation and amortization. We have defined Adjusted EBITDA as EBITDA plus (a) (income) loss from, and disposal of, discontinued operations, (b) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency gains and losses and loss on extinguishment of debt, and (c) certain items that we consider to be unusual, non-operational or non-recurring. The Adjusted EBITDA measure is not, and should not be viewed as, a substitute for GAAP reported net income.
The Adjusted EBITDA measure is an important internal measurement for us. We measure our overall performance on this basis in conjunction with other performance metrics. The following are examples of how our Adjusted EBITDA measure is utilized:
•
senior management receives a monthly analysis of our operating results that is prepared on an Adjusted EBITDA basis;
​
•
our annual budgets are prepared on an Adjusted EBITDA basis; and
​
•
other goal setting and performance measurements are prepared on an Adjusted EBITDA basis.
​
Despite the importance of this measure to management in goal setting and performance measurement, Adjusted EBITDA is a non-GAAP financial measure that has no standardized meaning prescribed by GAAP and, therefore, has limits in its usefulness to investors. Because of its non-standardized definition, Adjusted EBITDA, unlike GAAP net income, may not be comparable to the calculation of similar measures of other companies. We present Adjusted EBITDA to permit investors to more fully understand how management assesses performance.
We also recognize that, as an internal measure of performance, the Adjusted EBITDA measure has limitations, and we do not restrict our performance management process solely to this metric. A limitation of the Adjusted EBITDA measure is that it provides a view of our operations without including all events during a period, such as the depreciation of property, plant and equipment or amortization of purchased intangibles, and does not provide a comparable view of our performance to other companies.
Certain significant items
Adjusted EBITDA is calculated prior to considering certain items. We evaluate such items on an individual basis. Such evaluation considers both the quantitative and the qualitative aspect of their unusual or non-operational nature. Unusual, in this context, may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis.
31

TABLE OF CONTENTS
We consider acquisition-related activities and business restructuring costs related to productivity and cost saving initiatives, including employee separation costs, to be unusual items that we do not expect to occur as part of our normal business on a regular basis. We consider foreign currency gains and losses to be non-operational because they arise principally from intercompany transactions and are largely non-cash in nature.
New accounting standards
We adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), effective July 1, 2019.
For discussion of new accounting standards, see “Notes to Consolidated Financial Statements—Summary of Significant Accounting Policies and New Accounting Standards.”
Critical Accounting Policies
Critical accounting policies are those that require application of management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Not all of these significant accounting policies require management to make difficult, subjective or complex judgments or estimates. However, management is required to make certain estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. Significant estimates include depreciation and amortization periods of long-lived and intangible assets, recoverability of long-lived and intangible assets and goodwill, realizability of deferred income tax and value-added tax assets, assessment of the incremental borrowing rates and reasonably certain renewal periods associated with our lease agreements, legal and environmental matters and actuarial assumptions related to our pension plans. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the period they are determined to be necessary. Actual results could differ from those estimates. Our significant accounting policies are described in the notes to the consolidated financial statements included in the Annual Report. As of December 31, 2019, there have been no material changes to any of the critical accounting policies contained therein, other than those related to the adoption of the new lease standard, ASU 2016-02, Leases (Topic 842). See “Notes to Consolidated Financial Statements—Summary of Significant Accounting Policies and New Accounting Standards” for the changes made to our lease accounting policy.
Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this report are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “believe,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. For example, all statements we make relating to our estimated and projected earnings, revenues, costs, expenditures, cash flows, growth rates and financial results, our plans and objectives for future operations, growth or initiatives, strategies, or the expected outcome or impact of pending or threatened litigation are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Examples of such risks and uncertainties include:
•
perceived adverse effects on human health linked to the consumption of food derived from animals that utilize our products could cause a decline in the sales of those products;
​
​
32

TABLE OF CONTENTS
•
restrictions on the use of antibacterials in food-producing animals may become more prevalent;
​
•
a material portion of our sales and gross profits are generated by antibacterials and other related products;
​
•
competition in each of our markets from a number of large and small companies, some of which have greater financial, research and development (“R&D”), production and other resources than we have;
​
•
outbreaks of animal diseases could significantly reduce demand for our products;
​
•
our business may be negatively affected by weather conditions and the availability of natural resources;
​
•
the continuing trend toward consolidation of certain customer groups as well as the emergence of large buying groups;
​
•
our ability to control costs and expenses;
​
•
any unforeseen material loss or casualty;
​
•
exposure relating to rising costs and reduced customer income;
​
•
competition deriving from advances in veterinary medical practices and animal health technologies;
​
•
unanticipated safety or efficacy concerns;
​
•
our dependence on suppliers having current regulatory approvals;
​
•
our raw materials are subject to price fluctuations and their availability can be limited;
​
•
natural and man-made disasters, including but not limited to fire, snow and ice storms, flood, hail, hurricanes and earthquakes;
​
•
terrorist attacks, particularly attacks on or within markets in which we operate;
​
•
our ability to successfully implement our strategic initiatives;
​
•
our reliance on the continued operation of our manufacturing facilities and application of our intellectual property;
​
•
adverse U.S. and international economic market conditions, including currency fluctuations;
​
•
failure of our product approval, R&D, acquisition and licensing efforts to generate new products;
​
•
the risks of product liability claims, legal proceedings and general litigation expenses;
​
•
the impact of current and future laws and regulatory changes;
​
•
modification of foreign trade policy may harm our food animal product customers
​
•
our dependence on our Israeli and Brazilian operations;
​
•
our substantial level of indebtedness and related debt-service obligations;
​
•
restrictions imposed by covenants in our debt agreements;
​
•
the risk of work stoppages; and
​
•
other factors as described in “Risk Factors” in Item 1A. of our Annual Report on Form 10-K.
​
While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, or
33

TABLE OF CONTENTS​​
cautionary statements, are disclosed under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” All forward-looking statements are expressly qualified in their entirety by these cautionary statements. You should evaluate all forward-looking statements made in this report in the context of these risks and uncertainties.
We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences we anticipate or affect us or our operations in the way we expect. The forward-looking statements included in this report are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. If we do update one or more forward-looking statements, no inference should be made that we will make additional updates with respect to those or other forward-looking statements.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
In the normal course of operations, we are exposed to market risks arising from adverse changes in interest rates, foreign currency exchange rates and commodity prices. As a result, future earnings, cash flows and fair values of assets and liabilities are subject to uncertainty. We use, from time to time, foreign currency contracts and interest rate swaps as a means of hedging exposure to foreign currency risks and fluctuating interest rates, respectively. We do not utilize derivative instruments for trading or speculative purposes. We do not hedge our exposure to market risks in a manner that completely eliminates the effects of changing market conditions on earnings, cash flows and fair values. We monitor the financial stability and credit standing of our major counterparties.
For financial market risks related to changes in interest rates and foreign currency exchange rates, reference is made to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Qualitative and Quantitative Disclosures about Market Risk” section in the Annual Report and to the notes to the consolidated financial statements included therein. There were no material changes in the Company’s financial market risks from the risks disclosed in the Annual Report.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
An evaluation was carried out under the supervision and with the participation of the Company’s management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)). Based upon that evaluation as of December 31, 2019, our Chief Executive Officer and Chief Financial Officer each concluded that, as of the end of such period, our disclosure controls and procedures were not effective because of material weaknesses in our internal control over financial reporting, as described in Management’s Report on Internal Control over Financial Reporting in “Item 9A. Controls and Procedures” in the Annual Report on Form 10-K for the year ended June 30, 2019.
Material Weakness Remediation Efforts
We continue to make further progress in implementing a broad range of changes to our internal control over financial reporting to remediate the material weaknesses described in this item. Our actions to address the material weaknesses have included the design and implementation of additional formal accounting policies and procedures to ensure transactions are properly initiated, recorded, processed, reported, appropriately authorized and approved. Also, our efforts to ensure maintenance of the appropriate level of segregation of duties includes restricting access to key financial systems and records to appropriate users. We continue to make improvements by reducing the number of segregation of duties conflicts and continue to evaluate the extent it is necessary to limit access and modify responsibilities of certain personnel, as well as designing and implementing additional user access controls and compensating controls. We have completed a gap analysis of our key controls. In completing this analysis, we identified areas where new controls were needed and enhancements to existing controls, policies and procedures need
34

TABLE OF CONTENTS
to be made. Through this analysis, we have developed a workplan for remediation of our material weaknesses. The remediation plan includes enhancing and supplementing the finance team by increasing the number of roles, reassigning responsibilities, and adding additional resources with an appropriate level of knowledge and experience in internal control over financial reporting commensurate with our financial reporting requirements. We will continue to build on the progress we have made in our remediation plan. We cannot determine when our remediation plan will be fully completed, and we cannot provide any assurance that these remediation efforts will be successful or that our internal control over financial reporting will be effective as a result of these efforts.
Changes in Internal Control over Financial Reporting
There have been no changes in internal control over financial reporting during the three months ended December 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
35

TABLE OF CONTENTS​​​​​​​
PART II—OTHER INFORMATION
Item 1.
Legal Proceedings
​
Information required by this Item is incorporated herein by reference to “Notes to the Consolidated Financial Statements—Commitments and Contingencies” in Part I, Item 1, of this Quarterly Report on Form 10-Q.
Item 1A.
Risk Factors
​
In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the “Risk Factors” section in the Annual Report, which could materially affect our business, financial condition or future results.
There were no material changes in the Company’s risk factors from the risks disclosed in the Annual Report.
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
​
None.
Item 3.
Defaults Upon Senior Securities
​
None.
Item 4.
Mine Safety Disclosures
​
Not applicable.
Item 5.
Other Information
​
None.
Item 6.
Exhibits
​

​ | ​ | ​ | ​ | Exhibit 31.1 Chief Executive Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302 | ​
​ | ​ | ​ | ​ | Exhibit 31.2 Chief Financial Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302 | ​
​ | ​ | ​ | ​ | Exhibit 32.1 Chief Executive Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906 | ​
​ | ​ | ​ | ​ | Exhibit 32.2 Chief Financial Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906 | ​
​ | ​ | ​ | ​ | Exhibit 101.INS* XBRL Instance Document | ​
​ | ​ | ​ | ​ | Exhibit 101.SCH* XBRL Taxonomy Extension Schema Document | ​
​ | ​ | ​ | ​ | Exhibit 101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document | ​
​ | ​ | ​ | ​ | Exhibit 101.DEF* XBRL Taxonomy Extension Definition Linkbase Document | ​
​ | ​ | ​ | ​ | Exhibit 101.LAB* XBRL Taxonomy Extension Label Linkbase Document | ​
​ | ​ | ​ | ​ | Exhibit 101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document | ​

​
*
Furnished with this Quarterly Report. Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933 and are deemed not filed for purposes of section 18 of the Exchange Act.
​
​
36

TABLE OF CONTENTS​
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​ | ​ | ​ | ​ | Phibro Animal Health Corporation | ​
​ | February 3, 2020 | ​ | ​ | By: | ​ | ​ | /s/ Jack C. Bendheim ​ Jack C. Bendheim Chairman, President and Chief Executive Officer | ​
​ | February 3, 2020 | ​ | ​ | By: | ​ | ​ | /s/ Richard G. Johnson ​ Richard G. Johnson Chief Financial Officer | ​

37